Recent from talks
Nothing was collected or created yet.
Birth defect
View on Wikipedia| Birth defect | |
|---|---|
| Other names | Congenital disorder, congenital disease, congenital deformity, congenital anomaly[1] |
| Incomplete cleft lip | |
| Specialty | Medical genetics, pediatrics |
| Symptoms | Physical disability, intellectual disability, developmental disability[2] |
| Usual onset | Present at birth[2] |
| Types | Structural, functional[3] |
| Causes | Genetics, exposure to certain medications or chemicals, certain infections during pregnancy[4] |
| Risk factors | Insufficient folic acid, drinking alcohol or smoking, poorly controlled diabetes, mother over the age of 35[5][6] |
| Treatment | Therapy, medication, surgery, assistive technology[7] |
| Frequency | 3% of newborns (US)[8] |
| Deaths | 628,000 (2015)[9] |
A birth defect[a] is an abnormal condition that is present at birth, regardless of its cause.[2] Birth defects may result in disabilities that may be physical, intellectual, or developmental.[2] The disabilities can range from mild to severe.[6] Birth defects are divided into two main types: structural disorders in which problems are seen with the shape of a body part and functional disorders in which problems exist with how a body part works.[3] Functional disorders include metabolic and degenerative disorders.[3] Some birth defects include both structural and functional disorders.[3]
Birth defects may result from genetic or chromosomal disorders, exposure to certain medications or chemicals, or certain infections during pregnancy.[4] Risk factors include folate deficiency, drinking alcohol or smoking during pregnancy, poorly controlled diabetes, and a mother over the age of 35 years old.[5][6] Many birth defects are believed to involve multiple factors.[6] Birth defects may be visible at birth or diagnosed by screening tests.[10] A number of defects can be detected before birth by different prenatal tests.[10]
Treatment varies depending on the defect in question.[7] This may include therapy, medication, surgery, or assistive technology.[7] Birth defects affected about 96 million people as of 2015[update].[11] In the United States, they occur in about 3% of newborns.[8] They resulted in about 628,000 deaths in 2015, down from 751,000 in 1990.[9][12] The types with the greatest numbers of deaths are congenital heart disease (303,000), followed by neural tube defects (65,000).[9]
Classification
[edit]Much of the language used for describing congenital conditions antedates genome mapping, and structural conditions are often considered separately from other congenital conditions. Many metabolic conditions are now known to have subtle structural expression, and structural conditions often have genetic links. Still, congenital conditions are often classified on a structural basis, organized when possible by primary organ system affected.[citation needed]
Primarily structural
[edit]Several terms are used to describe congenital abnormalities. (Some of these are also used to describe noncongenital conditions, and more than one term may apply in an individual condition.)
Terminology
[edit]- A congenital physical anomaly is an abnormality of the structure of a body part. It may or may not be perceived as a problem condition. Many, if not most, people have one or more minor physical anomalies if examined carefully. Examples of minor anomalies can include curvature of the fifth finger (clinodactyly), a third nipple, tiny indentations of the skin near the ears (preauricular pits), shortness of the fourth metacarpal or metatarsal bones, or dimples over the lower spine (sacral dimples). Some minor anomalies may be clues to more significant internal abnormalities.[citation needed]
- Birth defect is a widely used term for a congenital malformation, i.e. a congenital, physical anomaly that is recognizable at birth, and which is significant enough to be considered a problem. According to the Centers for Disease Control and Prevention (CDC), most birth defects are believed to be caused by a complex mix of factors including genetics, environment, and behaviors,[13] though many birth defects have no known cause. An example of a birth defect is cleft palate, which occurs during the fourth through seventh weeks of gestation.[14] Body tissue and special cells from each side of the head grow toward the center of the face. They join to make the face.[14] A cleft means a split or separation; the "roof" of the mouth is called the palate.[15]
- A congenital malformation is a physical anomaly that is deleterious, i.e. a structural defect perceived as a problem. A typical combination of malformations affecting more than one body part is referred to as a malformation syndrome.[citation needed]
- Some conditions are due to abnormal tissue development:
- Conditions also can arise after tissue is formed:
- A deformation is a condition arising from mechanical stress to normal tissue.[16] Deformations often occur in the second or third trimester, and can be due to oligohydramnios.[citation needed]
- A disruption involves breakdown of normal tissues.[16]
- When multiple effects occur in a specified order, they are known as a sequence. When the order is not known, it is a syndrome.
Examples of primarily structural congenital disorders
[edit]A limb anomaly is called a dysmelia. These include all forms of limbs anomalies, such as amelia, ectrodactyly, phocomelia, polymelia, polydactyly, syndactyly, polysyndactyly, oligodactyly, brachydactyly, achondroplasia, congenital aplasia or hypoplasia, amniotic band syndrome, and cleidocranial dysostosis.[17]
Congenital heart defects include patent ductus arteriosus, atrial septal defect, ventricular septal defect, and tetralogy of Fallot.
Congenital anomalies of the nervous system include neural tube defects such as spina bifida, encephalocele, and anencephaly. Other congenital anomalies of the nervous system include the Arnold–Chiari malformation, the Dandy–Walker malformation, hydrocephalus, microencephaly, megalencephaly, lissencephaly, polymicrogyria, holoprosencephaly, and agenesis of the corpus callosum.[18]
Congenital anomalies of the gastrointestinal system include numerous forms of stenosis and atresia, and perforation, such as gastroschisis.[19]
Congenital anomalies of the kidney and urinary tract include renal parenchyma, kidneys, and urinary collecting system.[20]
Defects can be bilateral or unilateral, and different defects often coexist in an individual child.[21]
Primarily metabolic
[edit]A congenital metabolic disease is also referred to as an inborn error of metabolism. Most of these are single-gene defects, usually heritable. Many affect the structure of body parts, but some simply affect the function.[22]
Other
[edit]Other well-defined genetic conditions may affect the production of hormones, receptors, structural proteins, and ion channels.[citation needed]
Causes
[edit]Alcohol exposure
[edit]The mother's consumption of alcohol during pregnancy can cause a continuum of various permanent birth defects: craniofacial abnormalities,[23] brain damage,[24] intellectual disability,[25] heart disease, kidney abnormality, skeletal anomalies, ocular abnormalities.[26] There is no known safe amount of alcohol to consume while pregnant.[27]
The prevalence of children affected is estimated at least 1% in U.S.[28] as well in Canada.
Very few studies have investigated the links between paternal alcohol use and offspring health.[29]
However, recent animal research has shown a correlation between paternal alcohol exposure and decreased offspring birth weight. Behavioral and cognitive disorders, including difficulties with learning and memory, hyperactivity, and lowered stress tolerance have been linked to paternal alcohol ingestion.[30] The compromised stress management skills of animals whose male parent was exposed to alcohol are similar to the exaggerated responses to stress that children with fetal alcohol syndrome display because of maternal alcohol use. These birth defects and behavioral disorders were found in cases of both long- and short-term paternal alcohol ingestion.[31][32] In the same animal study, paternal alcohol exposure was correlated with a significant difference in organ size and the increased risk of the offspring displaying ventricular septal defects at birth.[32]
Toxic substances
[edit]Substances whose toxicity can cause congenital disorders are called teratogens, and include certain pharmaceutical and recreational drugs in pregnancy, as well as many environmental toxins in pregnancy.[33]
A review published in 2010 identified six main teratogenic mechanisms associated with medication use: folate antagonism, neural crest cell disruption, endocrine disruption, oxidative stress, vascular disruption, and specific receptor- or enzyme-mediated teratogenesis.[34]
An estimated 10% of all birth defects are caused by prenatal exposure to a teratogenic agent.[35] These exposures include medication or drug exposures, maternal infections and diseases, and environmental and occupational exposures. Paternal smoking has also been linked to an increased risk of birth defects and childhood cancer for the offspring, where the paternal germline undergoes oxidative damage due to cigarette use.[36][37] Teratogen-caused birth defects are potentially preventable. Nearly 50% of pregnant women have been exposed to at least one medication during gestation.[38] During pregnancy, a woman can also be exposed to teratogens from contaminated clothing or toxins within the seminal fluid of a partner.[39][31][40] An additional study found that of 200 individuals referred for genetic counseling for a teratogenic exposure, 52% were exposed to more than one potential teratogen.[41]
The United States Environmental Protection Agency studied 1,065 chemical and drug substances in their ToxCast program (part of the CompTox Chemicals Dashboard) using in silico modeling and a human pluripotent stem cell-based assay to predict in vivo developmental intoxicants based on changes in cellular metabolism following chemical exposure. Findings of the study published in 2020 were that 19% of the 1065 chemicals yielded a prediction of developmental toxicity.[42]
Medications and supplements
[edit]Probably, the most well-known teratogenic drug is thalidomide. It was developed near the end of the 1950s by Chemie Grünenthal as a sleep-inducing aid and antiemetic. Because of its ability to prevent nausea, it was prescribed for pregnant women in almost 50 countries worldwide between 1956 and 1962.[43] Until William McBride published the study leading to its withdrawal from the market in 1961, about 8,000 to 10,000 severely malformed children were born. The most typical disorders induced by thalidomide were reductional deformities of the long bones of the extremities. Phocomelia, otherwise a rare deformity, therefore helped to recognise the teratogenic effect of the new drug. Among other malformations caused by thalidomide were those of ears, eyes, brain, kidney, heart, and digestive and respiratory tracts; 40% of the prenatally affected children died soon after birth.[43] As thalidomide is used today as a treatment for multiple myeloma and leprosy, several births of affected children were described in spite of the strictly required use of contraception among female patients treated by it.[citation needed]
Vitamin A is the sole vitamin that is embryotoxic even in a therapeutic dose, for example in multivitamins, because its metabolite, retinoic acid, plays an important role as a signal molecule in the development of several tissues and organs. Its natural precursor, β-carotene, is considered safe, whereas the consumption of animal liver can lead to malformation, as the liver stores lipophilic vitamins, including retinol.[43] Isotretinoin (13-cis-retinoic-acid; brand name Roaccutane), vitamin A analog, which is often used to treat severe acne, is such a strong teratogen that just a single dose taken by a pregnant woman (even transdermally) may result in serious birth defects. Because of this effect, most countries have systems in place to ensure that it is not given to pregnant women and that the patient is aware of how important it is to prevent pregnancy during and at least one month after treatment. Medical guidelines also suggest that pregnant women should limit vitamin A intake to about 700 μg/day, as it has teratogenic potential when consumed in excess.[44][45] Vitamin A and similar substances can induce spontaneous abortions, premature births, defects of eyes (microphthalmia), ears, thymus, face deformities, and neurological (hydrocephalus, microcephalia) and cardiovascular defects, as well as intellectual disability.[43]
Tetracycline, an antibiotic, should never be prescribed to women of reproductive age or to children, because of its negative impact on bone mineralization and teeth mineralization. The "tetracycline teeth" have brown or grey colour as a result of a defective development of both the dentine and the enamel of teeth.[43]
Several anticonvulsants are known to be highly teratogenic. Phenytoin, also known as diphenylhydantoin, along with carbamazepine, is responsible for the fetal hydantoin syndrome, which may typically include broad nose base, cleft lip and/or palate, microcephalia, nails and fingers hypoplasia, intrauterine growth restriction, and intellectual disability. Trimethadione taken during pregnancy is responsible for the fetal trimethadione syndrome, characterized by craniofacial, cardiovascular, renal, and spine malformations, along with a delay in mental and physical development. Valproate has antifolate effects, leading to neural tube closure-related defects such as spina bifida. Lower IQ and autism have recently also been reported as a result of intrauterine valproate exposure.[43]
Hormonal contraception is considered harmless for the embryo. Peterka and Novotná[43] do, however, state that synthetic progestins used to prevent miscarriage in the past frequently caused masculinization of the outer reproductive organs of female newborns due to their androgenic activity. Diethylstilbestrol is a synthetic estrogen used from the 1940s to 1971, when the prenatal exposition has been linked to the clear-cell adenocarcinoma of the vagina. Following studies showed elevated risks for other tumors and congenital malformations of the sex organs for both sexes.[citation needed]
All cytostatics are strong teratogens; abortion is usually recommended when pregnancy is discovered during or before chemotherapy. Aminopterin, a cytostatic drug with antifolate effect, was used during the 1950s and 1960s to induce therapeutic abortions. In some cases, the abortion did not happen, but the newborns had a fetal aminopterin syndrome consisting of growth retardation, craniosynostosis, hydrocephalus, facial dismorphities, intellectual disability, or leg deformities[43][46]
Toxic substances
[edit]Drinking water is often a medium through which harmful toxins travel. Heavy metals, elements, nitrates, nitrites, and fluoride can be carried through water and cause congenital disorders.[47]
Nitrate, which is found mostly in drinking water from ground sources, is a powerful teratogen. A case-control study in rural Australia that was conducted following frequent reports of prenatal mortality and congenital malformations found that those who drank the nitrate-containing groundwater, as opposed to rain water, ran the risk of giving birth to children with central nervous system disorders, muscoskeletal defects, and cardiac defects.[48]
Chlorinated and aromatic solvents such as benzene and trichloroethylene sometimes enter the water supply due to oversights in waste disposal. A case-control study on the area found that by 1986, leukemia was occurring in the children of Woburn, Massachusetts, at a rate that was four times the expected rate of incidence. Further investigation revealed a connection between the high occurrence of leukemia and an error in water distribution that delivered water to the town with significant contamination with manufacturing waste containing trichloroethylene.[49] As an endocrine disruptor, DDT was shown to induce miscarriages, interfere with the development of the female reproductive system, cause congenital hypothyroidism, and increase the risk for childhood obesity.[43]
Fluoride, when transmitted through water at high levels, can also act as a teratogen. Two reports on fluoride exposure from China, which were controlled to account for the education level of parents, found that children born to parents who were exposed to 4.12 ppm fluoride grew to have IQs that were, on average, seven points lower than their counterparts whose parents consumed water that contained 0.91 ppm fluoride. In studies conducted on rats, higher fluoride in drinking water led to increased acetylcholinesterase levels, which can alter prenatal brain development. The most significant effects were noted at a level of 5 ppm.[50]
The fetus is even more susceptible to damage from carbon monoxide intake, which can be harmful when inhaled during pregnancy, usually through first- or second-hand tobacco smoke. The concentration of carbon monoxide in the infant born to a nonsmoking mother is around 2%, and this concentration drastically increases to a range of 6%–9% if the mother smoked tobacco. Other possible sources of prenatal carbon monoxide intoxication are exhaust gas from combustion motors, use of dichloromethane (paint thinner, varnish removers) in enclosed areas, defective gas water heaters, indoor barbeques, open flames in poorly ventilated areas, and atmospheric exposure in highly polluted areas.[51] Exposure to carbon monoxide at toxic levels during the first two trimesters of pregnancy can lead to intrauterine growth restriction, leading to a baby who has stunted growth and is born smaller than 90% of other babies at the same gestational age. The effect of chronic exposure to carbon monoxide can depend on the stage of pregnancy in which the mother is exposed. Exposure during the embryonic stage can have neurological consequences, such as telencephalic dysgenesis, behavioral difficulties during infancy, and reduction of cerebellum volume. Also, possible skeletal defects could result from exposure to carbon monoxide during the embryonic stage, such as hand and foot malformations, hip dysplasia, hip subluxation, agenesis of a limb, and inferior maxillary atresia with glossoptosis. Also, carbon monoxide exposure between days 35 and 40 of embryonic development can lead to an increased risk of the child developing a cleft palate. Exposure to carbon monoxide or polluted ozone exposure can also lead to cardiac defects of the ventrical septal, pulmonary artery, and heart valves.[52] The effects of carbon monoxide exposure are decreased later in fetal development during the fetal stage, but they may still lead to anoxic encephalopathy.[53]
Industrial pollution can also lead to congenital defects.[54] Over a period of 37 years, the Chisso Corporation, a petrochemical and plastics company, contaminated the waters of Minamata Bay with an estimated 27 tons of methylmercury, contaminating the local water supply. This led many people in the area to develop what became known as the "Minamata disease". Because methylmercury is a teratogen, the mercury poisoning of those residing by the bay resulted in neurological defects in the offspring. Infants exposed to mercury poisoning in utero showed predispositions to cerebral palsy, ataxia, inhibited psychomotor development, and intellectual disability.[55]
Landfill sites have been shown to have adverse effects on fetal development. Extensive research has shown that landfills have several negative effects on babies born to mothers living near landfill sites: low birth weight, birth defects, spontaneous abortion, and fetal and infant mortality. Studies done around the Love Canal site near Niagara Falls and the Lipari Landfill in New Jersey have shown a higher proportion of low birth-weight babies than communities farther away from landfills. A study done in California showed a positive correlation between time and quantity of dumping and low birth weights and neonatal deaths. A study in the United Kingdom showed a correlation between pregnant women living near landfill sites and an increased risk of congenital disorders, such as neural tube defects, hypospadias, epispadia, and abdominal wall defects, such as gastroschisis and exomphalos. A study conducted on a Welsh community also showed an increased incidence of gastroschisis. Another study on 21 European hazardous-waste sites showed that those living within 3 km had an increased risk of giving birth to infants with birth defects and that as distance from the land increased, the risk decreased. These birth defects included neural tube defects, malformations of the cardiac septa, anomalies of arteries and veins, and chromosomal anomalies.[56] Looking at communities that live near landfill sites brings up environmental justice. A vast majority of sites are located near poor, mostly black, communities. For example, between the early 1920s and 1978, about 25% of Houston's population was black. However, over 80% of landfills and incinerators during this time were located in these black communities.[57]
Another issue regarding environmental justice is lead poisoning. A fetus exposed to lead during the pregnancy can result in learning difficulties and slowed growth. Some paints (before 1978) and pipes contain lead. Therefore, pregnant women who live in homes with lead paint inhale the dust containing lead, leading to lead exposure in the fetus. When lead pipes are used for drinking water and cooking water, this water is ingested, along with the lead, exposing the fetus to this toxin. This issue is more prevalent in poorer communities because more well-off families are able to afford to have their homes repainted and pipes renovated.[58]
Endometriosis
[edit]Endometriosis can impact a woman's fetus, causing a 30% higher risk for congenital malformations and a 50% higher risk of neonates being under-sized for their gestational age.[59]
Smoking
[edit]Paternal smoking prior to conception has been linked with the increased risk of congenital abnormalities in offspring.[29]
Smoking causes DNA mutations in the germline of the father, which can be inherited by the offspring. Cigarette smoke acts as a chemical mutagen on germ cell DNA. The germ cells suffer oxidative damage, and the effects can be seen in altered mRNA production, infertility issues, and side effects in the embryonic and fetal stages of development. This oxidative damage may result in epigenetic or genetic modifications of the father's germline. Fetal lymphocytes have been damaged as a result of a father's smoking habits prior to conception.[37][39]
Correlations between paternal smoking and the increased risk of offspring developing childhood cancers (including acute leukemia, brain tumors, and lymphoma) before age five have been established. Little is currently known about how paternal smoking damages the fetus, and what window of time in which the father smokes is most harmful to offspring.[37]
Infections
[edit]A vertically transmitted infection is an infection caused by bacteria, viruses, or in rare cases, parasites transmitted directly from the mother to an embryo, fetus, or baby during pregnancy or childbirth.[60]
Congenital disorders were initially believed to be the result of only hereditary factors. However, in the early 1940s, Australian pediatric ophthalmologist Norman Gregg began recognizing a pattern in which the infants arriving at his surgery were developing congenital cataracts at a higher rate than those who developed it from hereditary factors.[61] On October 15, 1941, Gregg delivered a paper that explained his findings-68 out of the 78 children with congenital cataracts had been exposed in utero to rubella due to an outbreak in Australian army camps. These findings confirmed, to Gregg, that, in fact, environmental causes for congenital disorders could exist.[citation needed]
Rubella is known to cause abnormalities of the eye, internal ear, heart, and sometimes the teeth. More specifically, fetal exposure to rubella during weeks five to ten of development (the sixth week particularly) can cause cataracts and microphthalmia in the eyes. If the mother is infected with rubella during the ninth week, a crucial week for internal ear development, destruction of the organ of Corti can occur, causing deafness. In the heart, the ductus arteriosus can remain after birth, leading to hypertension. Rubella can also lead to atrial and ventricular septal defects in the heart. If exposed to rubella in the second trimester, the fetus can develop central nervous system malformations. However, because infections of rubella may remain undetected, misdiagnosed, or unrecognized in the mother, and/or some abnormalities are not evident until later in the child's life, precise incidence of birth defects due to rubella are not entirely known. The timing of the mother's infection during fetal development determines the risk and type of birth defect. As the embryo develops, the risk of abnormalities decreases. If exposed to the rubella virus during the first four weeks, the risk of malformations is 47%. Exposure during weeks five through eight creates a 22% chance, while weeks 9–12, a 7% chance exists, followed by 6% if the exposure is during the 13th-16th weeks. Exposure during the first eight weeks of development can also lead to premature birth and fetal death. These numbers are calculated from immediate inspection of the infant after birth. Therefore, mental defects are not accounted for in the percentages because they are not evident until later in the child's life. If they were to be included, these numbers would be much higher.[62]
Other infectious agents include cytomegalovirus, the herpes simplex virus, hyperthermia, toxoplasmosis, and syphilis. Maternal exposure to cytomegalovirus can cause microcephaly, cerebral calcifications, blindness, chorioretinitis (which can cause blindness), hepatosplenomegaly, and meningoencephalitis in fetuses.[62] Microcephaly is a disorder in which the fetus has an atypically small head,[63] cerebral calcifications means certain areas of the brain have atypical calcium deposits,[64] and meningoencephalitis is the enlargement of the brain. All three disorders cause abnormal brain function or intellectual disability. Hepatosplenomegaly is the enlargement of the liver and spleen which causes digestive problems.[65] It can also cause some kernicterus and petechiae. Kernicterus causes yellow pigmentation of the skin, brain damage, and deafness.[66] Petechaie is when the capillaries bleed resulting in red/purple spots on the skin.[67] However, cytomegalovirus is often fatal in the embryo. The Zika virus can also be transmitted from the pregnant mother to her baby and cause microcephaly.[citation needed]
The herpes simplex virus can cause microcephaly, microphthalmus (abnormally small eyeballs),[68] retinal dysplasia, hepatosplenomegaly, and intellectual disability.[62] Both microphthalmus and retinal dysplasia can cause blindness. However, the most common symptom in infants is an inflammatory response that develops during the first three weeks of life.[62] Hyperthermia causes anencephaly, which is when part of the brain and skull are absent in the infant.[62][69] Mother exposure to toxoplasmosis can cause cerebral calcification, hydrocephalus (causes mental disabilities),[70] and intellectual disability in infants. Other birth abnormalities have been reported as well, such as chorioretinitis, microphthalmus, and ocular defects. Syphilis causes congenital deafness, intellectual disability, and diffuse fibrosis in organs, such as the liver and lungs, if the embryo is exposed.[62]
Malnutrition
[edit]For example, a lack of folic acid, a B vitamin, in the diet of a mother can cause cellular neural tube deformities that result in spina bifida. Congenital disorders such as a neural tube deformity can be prevented by 72% if the mother consumes 4 mg of folic acid before the conception and after twelve weeks of pregnancy.[71] Folic acid, or vitamin B9, aids the development of the foetal nervous system.[71]
Studies with mice have found that food deprivation of the male mouse prior to conception leads to the offspring displaying significantly lower blood glucose levels.[72]
Physical restraint
[edit]External physical shocks or constraints due to growth in a restricted space may result in unintended deformation or separation of cellular structures resulting in an abnormal final shape or damaged structures unable to function as expected. An example is Potter syndrome due to oligohydramnios. This finding is important for future understanding of how genetics may predispose individuals for diseases such as obesity, diabetes, and cancer.[73]
For multicellular organisms that develop in a womb, the physical interference or presence of other similarly developing organisms such as twins can result in the two cellular masses being integrated into a larger whole, with the combined cells attempting to continue to develop in a manner that satisfies the intended growth patterns of both cell masses.[74] The two cellular masses can compete with each other, and may either duplicate or merge various structures. This results in conditions such as conjoined twins, and the resulting merged organism may die at birth when it must leave the life-sustaining environment of the womb and must attempt to sustain its biological processes independently.[citation needed]
Genetics
[edit]Genetic causes of birth defects include inheritance of abnormal genes from the mother or the father, as well as new mutations in one of the germ cells that gave rise to the fetus. Male germ cells mutate at a much faster rate than female germ cells, and as the father ages, the DNA of the germ cells mutates quickly.[36][75] If an egg is fertilized with sperm that has damaged DNA, a possibility exists that the fetus could develop abnormally.[75][76]
Genetic disorders are all congenital (present at birth), though they may not be expressed or recognized until later in life. Genetic disorders may be grouped into single-gene defects, multiple-gene disorders, or chromosomal defects. Single-gene defects may arise from abnormalities of both copies of an autosomal gene (a recessive disorder) or of only one of the two copies (a dominant disorder). Some conditions result from deletions or abnormalities of a few genes located contiguously on a chromosome. Chromosomal disorders involve the loss or duplication of larger portions of a chromosome (or an entire chromosome) containing hundreds of genes. Large chromosomal abnormalities always produce effects on many different body parts and organ systems.[citation needed]
Defective sperm
[edit]Non-genetic defects in sperm cells, such as deformed centrioles and other components in the tail and neck of the sperm which are important for the embryonic development, may result in defects.[77][78]
Socioeconomics
[edit]A low socioeconomic status in a deprived neighborhood may include exposure to "environmental stressors and risk factors".[79] Socioeconomic inequalities are commonly measured by the Cartairs-Morris score, Index of Multiple Deprivation, Townsend deprivation index, and the Jarman score.[80] The Jarman score, for example, considers "unemployment, overcrowding, single parents, under-fives, elderly living alone, ethnicity, low social class and residential mobility".[80] In Vos' meta-analysis these indices are used to view the effect of low SES neighborhoods on maternal health. In the meta-analysis, data from individual studies were collected from 1985 up until 2008.[80] Vos concludes that a correlation exists between prenatal adversities and deprived neighborhoods.[80] Other studies have shown that low SES is closely associated with the development of the fetus in utero and growth retardation.[81] Studies also suggest that children born in low SES families are "likely to be born prematurely, at low birth weight, or with asphyxia, a birth defect, a disability, fetal alcohol syndrome, or AIDS".[81] Bradley and Corwyn also suggest that congenital disorders arise from the mother's lack of nutrition, a poor lifestyle, maternal substance abuse and "living in a neighborhood that contains hazards affecting fetal development (toxic waste dumps)".[81] In a meta-analysis that viewed how inequalities influenced maternal health, it was suggested that deprived neighborhoods often promoted behaviors such as smoking, drug and alcohol use.[79] After controlling for socioeconomic factors and ethnicity, several individual studies demonstrated an association with outcomes such as perinatal mortality and preterm birth.[79]
Radiation
[edit]For the survivors of the atomic bombing of Hiroshima and Nagasaki, who are known as the Hibakusha, no statistically demonstrable increase of birth defects/congenital malformations was found among their later conceived children, or found in the later conceived children of cancer survivors who had previously received radiotherapy.[82][83][84][85] The surviving women of Hiroshima and Nagasaki who were able to conceive, though exposed to substantial amounts of radiation, later had children with no higher incidence of abnormalities/birth defects than in the Japanese population as a whole.[86][87]
Relatively few studies have researched the effects of paternal radiation exposure on offspring. Following the Chernobyl disaster, it was assumed in the 1990s that the germ line of irradiated fathers suffered minisatellite mutations in the DNA, which was inherited by descendants.[31][88] More recently, however, the World Health Organization states, "children conceived before or after their father's exposure showed no statistically significant differences in mutation frequencies".[89] This statistically insignificant increase was also seen by independent researchers analyzing the children of the liquidators.[90] Animal studies have shown that incomparably massive doses of X-ray irradiation of male mice resulted in birth defects of the offspring.[39]
In the 1980s, a relatively high prevalence of pediatric leukemia cases in children living near a nuclear processing plant in West Cumbria, UK, led researchers to investigate whether the cancer was a result of paternal radiation exposure. A significant association between paternal irradiation and offspring cancer was found, but further research areas close to other nuclear processing plants did not produce the same results.[39][31] Later this was determined to be the Seascale cluster in which the leading hypothesis is the influx of foreign workers, who have a different rate of leukemia within their race than the British average, resulted in the observed cluster of 6 children more than expected around Cumbria.[91]
Parent's age
[edit]Certain birth complications can occur more often in advanced maternal age (greater than 35 years). Complications include fetal growth restriction, preeclampsia, placental abruption, pre-mature births, and stillbirth. These complications not only may put the child at risk, but also the mother.[92]
The effects of the father's age on offspring are not yet well understood and are studied far less extensively than the effects of the mother's age.[93] Fathers contribute proportionally more DNA mutations to their offspring via their germ cells than the mother, with the paternal age governing how many mutations are passed on. This is because, as humans age, male germ cells acquire mutations at a much faster rate than female germ cells.[36][39][75]
Around a 5% increase in the incidence of ventricular septal defects, atrial septal defects, and patent ductus arteriosus in offspring has been found to be correlated with advanced paternal age. Advanced paternal age has also been linked to increased risk of achondroplasia and Apert syndrome. Offspring born to fathers under the age of 20 show increased risk of being affected by patent ductus arteriosus, ventricular septal defects, and the tetralogy of Fallot. It is hypothesized that this may be due to environmental exposures or lifestyle choices.[93]
Research has found that there is a correlation between advanced paternal age and risk of birth defects such as limb anomalies, syndromes involving multiple systems, and Down syndrome.[75][36][94] Recent studies have concluded that 5–9% of Down syndrome cases are due to paternal effects, but these findings are controversial.[75][76][36][95]
There is concrete evidence that advanced paternal age is associated with the increased likelihood that a mother will have a miscarriage or that fetal death will occur.[75]
Unknown
[edit]Although significant progress has been made in identifying the etiology of some birth defects, approximately 65% have no known or identifiable cause.[35] These are referred to as sporadic, a term that implies an unknown cause, random occurrence regardless of maternal living conditions,[96] and a low recurrence risk for future children. For 20–25% of anomalies there seems to be a "multifactorial" cause, meaning a complex interaction of multiple minor genetic anomalies with environmental risk factors. Another 10–13% of anomalies have a purely environmental cause (e.g. infections, illness, or drug abuse in the mother). Only 12–25% of anomalies have a purely genetic cause. Of these, the majority are chromosomal anomalies.[97]
Congenital disorders are not limited to humans and can be found in a variety of other species, including cattle. One such condition is called schistosomus reflexus and is defined by spinal inversion, exposure of abdominal viscera, and limb abnormalities.[98]
Prevention
[edit]Folate supplements decrease the risk of neural tube defects. Tentative evidence supports the role of L-arginine in decreasing the risk of intrauterine growth restriction.[99]
Screening
[edit]Newborn screening tests were introduced in the early 1960s and initially dealt with just two disorders. Since then tandem mass spectrometry, gas chromatography–mass spectrometry, and DNA analysis has made it possible for a much larger range of disorders to be screened. Newborn screening mostly measures metabolite and enzyme activity using a dried blood spot sample.[100] Screening tests are carried out in order to detect serious disorders that may be treatable to some extent.[101] Early diagnosis makes possible the readiness of therapeutic dietary information, enzyme replacement therapy and organ transplants.[102] Different countries support the screening for a number of metabolic disorders (inborn errors of metabolism (IEM)), and genetic disorders including cystic fibrosis and Duchenne muscular dystrophy.[101][103] Tandem mass spectroscopy can also be used for IEM, and investigation of sudden infant death, and shaken baby syndrome.[101]
Screening can also be carried out prenatally and can include obstetric ultrasonography to give scans such as the nuchal scan. 3D ultrasound scans can give detailed information of structural anomalies.[citation needed]
Epidemiology
[edit]

Congenital anomalies resulted in about 632,000 deaths per year in 2013 down from 751,000 in 1990.[12] The types with the greatest death are congenital heart defects (323,000), followed by neural tube defects (69,000).[12]
Many studies have found that the frequency of occurrence of certain congenital malformations depends on the sex of the child (table).[105][106][107][108][109] For example, pyloric stenosis occurs more often in males while congenital hip dislocation is four to five times more likely to occur in females. Among children with one kidney, there are approximately twice as many males, whereas among children with three kidneys there are approximately 2.5 times more females. The same pattern is observed among infants with excessive number of ribs, vertebrae, teeth and other organs which in a process of evolution have undergone reduction—among them there are more females. Contrarily, among the infants with their scarcity, there are more males. Anencephaly is shown to occur approximately twice as frequently in females.[110] The number of boys born with 6 fingers is two times higher than the number of girls.[111] Now various techniques are available to detect congenital anomalies in fetus before birth.[112]
About 3% of newborns have a "major physical anomaly", meaning a physical anomaly that has cosmetic or functional significance.[113] Physical congenital abnormalities are the leading cause of infant mortality in the United States, accounting for more than 20% of all infant deaths. Seven to ten percent of all children[clarification needed] will require extensive medical care to diagnose or treat a birth defect.[114]
The sex ratio of patients with congenital malformations Congenital anomaly Sex ratio, ♂♂:♀♀ Defects with female predominance Congenital hip dislocation 1 : 5.2;[115] 1 : 5;[116] 1 : 8;[109] 1 : 3.7[117] Cleft palate 1 : 3[116] Anencephaly 1 : 1.9;[115] 1 : 2[110] Craniocele 1 : 1.8[115] Aplasia of lung 1 : 1.51[115] Spinal herniation 1 : 1.4[115] Diverticulum of the esophagus 1 : 1.4[115] Stomach 1 : 1.4[115] Neutral defects Hypoplasia of the tibia and femur 1 : 1.2[115] Spina bifida 1 : 1.2[117] Atresia of small intestine 1 : 1[115] Microcephaly 1.2 : 1[117] Esophageal atresia 1.3 : 1;[115] 1.5 : 1[117] Hydrocephalus 1.3 : 1[117] Defects with male predominance Diverticula of the colon 1.5 : 1[115] Atresia of the rectum 1.5 : 1;[115] 2 : 1[117] Unilateral renal agenesis 2 : 1;[115] 2.1 : 1[117] Schistocystis 2 : 1[115] Cleft lip and palate 2 : 1;[116] 1.47 : 1[117] Bilateral renal agenesis 2.6 : 1[115] Congenital anomalies of the genitourinary system 2.7 : 1[109] Pyloric stenosis, congenital 5 : 1;[116] 5.4 : 1[109] Meckel's diverticulum More common in boys[115] Congenital megacolon More common in boys[115] All defects 1.22 : 1;[118] 1.29 : 1[109]
P. M. Rajewski and A. L. Sherman (1976) have analyzed the frequency of congenital anomalies in relation to the system of the organism. Prevalence of men was recorded for the anomalies of phylogenetically younger organs and systems.[115]
In respect of an etiology, sexual distinctions can be divided on appearing before and after differentiation of male's gonads during embryonic development, which begins from the eighteenth week. The testosterone level in male embryos thus raises considerably.[119] The subsequent hormonal and physiological distinctions of male and female embryos can explain some sexual differences in frequency of congenital defects.[120] It is difficult to explain the observed differences in the frequency of birth defects between the sexes by the details of the reproductive functions or the influence of environmental and social factors.[citation needed]
United States
[edit]The CDC and National Birth Defect Project studied the incidence of birth defects in the US. Key findings include:[citation needed]
- Down syndrome was the most common condition with an estimated prevalence of 14.47 per 10,000 live births, implying about 6,000 diagnoses each year.
- About 7,000 babies are born with a cleft palate, cleft lip or both.
| Birth Defects | Cases per Births | Estimated Annual Number of Cases | Estimated National Prevalence per 10,000 Live Births (Adjusted for maternal race/ethnicity) |
|---|---|---|---|
| Central nervous system defects | |||
| Anencephaly | 1 in 4,859 | 859 | 2.06 |
| Spina bifida without anencephaly | 1 in 2,858 | 1460 | 3.50 |
| Encephalocele | 1 in 12,235 | 341 | 0.82 |
| Eye defects | |||
| Anophthalmia/ microphthalmia | 1 in 5,349 | 780 | 1.87 |
| Cardiovascular defects | |||
| Common truncus | 1 in 13,876 | 301 | 0.72 |
| Transposition of great arteries | 1 in 3,333 | 1252 | 3.00 |
| Tetralogy of Fallot | 1 in 2,518 | 1657 | 3.97 |
| Atrioventricular septal defect | 1 in 2,122 | 1966 | 4.71 |
| Hypoplastic left heart syndrome | 1 in 4,344 | 960 | 2.30 |
| Orofacial defects | |||
| Cleft palate without cleft lip | 1 in 1,574 | 2651 | 6.35 |
| Cleft lip with and without cleft palate | 1 in 940 | 4437 | 10.63 |
| Gastrointestinal defects | |||
| Esophageal atresia/tracheoeophageal fistula | 1 in 4,608 | 905 | 2.17 |
| Rectal and large intestinalatresia/stenosis | 1 in 2,138 | 1952 | 4.68 |
| Musculoskeletal defects | |||
| Clubfoot, lower limbs | 1 in 250 ~ 1000 | ... | ... |
| Reduction deformity, upper limbs | 1 in 2,869 | 1454 | 3.49 |
| Reduction deformity, lower limbs | 1 in 5,949 | 701 | 1.68 |
| Gastroschisis | 1 in 2,229 | 1871 | 4.49 |
| Omphalocele | 1 in 5,386 | 775 | 1.86 |
| Diaphragmatic hernia | 1 in 3,836 | 1088 | 2.61 |
| Chromosomal anomalies | |||
| Trisomy 13 | 1 in 7,906 | 528 | 1.26 |
| Trisomy 21 (Down syndrome) | 1 in 691 | 6037 | 14.47 |
| Trisomy 18 | 1 in 3,762 | 1109 | 2.66 |
See also
[edit]Notes
[edit]- ^ Also known as a congenital disorder, congenital disease, congenital deformity, or congenital anomaly.
References
[edit]- ^ Ruth A. Hannon (2010). Porth pathophysiology: concepts of altered health states (1st Canadian ed.). Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 128. ISBN 978-1-60547-781-7.
- ^ a b c d "Birth Defects: Condition Information". www.nichd.nih.gov. September 2017. Archived from the original on 22 December 2017. Retrieved 8 December 2017.
- ^ a b c d "What are the types of birth defects?". www.nichd.nih.gov. September 2017. Archived from the original on 22 December 2017. Retrieved 8 December 2017.
- ^ a b "What causes birth defects?". www.nichd.nih.gov. September 2017. Archived from the original on 17 December 2017. Retrieved 8 December 2017.
- ^ a b "How many people are affected by/at risk for birth defects?". www.nichd.nih.gov. Archived from the original on 17 December 2017. Retrieved 8 December 2017.
- ^ a b c d "What are Birth Defects?". Centers for Disease Control and Prevention. 7 September 2017. Archived from the original on 15 June 2018. Retrieved 14 April 2023.
- ^ a b c "What are the treatments for birth defects?". www.nichd.nih.gov. September 2017. Archived from the original on 20 December 2017. Retrieved 8 December 2017.
- ^ a b "Birth Defects". Dec 15, 2015. Archived from the original on 18 June 2018. Retrieved 17 Jan 2016.
- ^ a b c Wang, Haidong; et al. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- ^ a b "How do health care providers diagnose birth defects?". www.nichd.nih.gov. September 2017. Archived from the original on 22 December 2017. Retrieved 8 December 2017.
- ^ Vos, Theo; et al. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- ^ a b c GBD 2013 Mortality and Causes of Death Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
- ^ Birth Defects Research Archived 2015-09-24 at the Wayback Machine. Centers for Disease Control and Prevention.
- ^ a b "Facts about Cleft Lip and Cleft Palate | Birth Defects | NCBDDD | CDC". www.cdc.gov. Archived from the original on 2015-05-08. Retrieved 2016-03-16.
- ^ communications. "Cleft Lip and Cleft Palate". American Academy of Otolaryngology–Head and Neck Surgery. Archived from the original on 2016-03-21. Retrieved 2016-03-16.
- ^ a b c d Graham, John Whichello (2007). Smith's Recognizable Patterns of Human Deformation, 3rd Edition. Philadelphia: Saunders. p. 3. ISBN 978-0-7216-1489-2.
- ^ Tayel, SM; Fawzia, MM; Al-Naqeeb, Niran A; Gouda, Said; Al Awadi, SA; Naguib, KK (2005). "A morpho-etiological description of congenital limb anomalies". Annals of Saudi Medicine. 25 (3): 219–227. doi:10.5144/0256-4947.2005.219. ISSN 0256-4947. PMC 6147980. PMID 16119523.
- ^ Gaitanis, John; Tarui, Tomo (2018). "Nervous System Malformations". CONTINUUM: Lifelong Learning in Neurology. 24 (1): 72–95. doi:10.1212/CON.0000000000000561. ISSN 1080-2371. PMC 6463295. PMID 29432238.
- ^ CDC (2021-03-31). "Congenital Anomalies of the Digestive System". Centers for Disease Control and Prevention. Archived from the original on 2022-10-31. Retrieved 2022-10-31.
- ^ "Overview of congenital anomalies of the kidney and urinary tract (CAKUT)". UpToDate – Wolters Kluer Health. Archived from the original on 27 June 2012. Retrieved 29 October 2012.
- ^ Jain, Sanjay; Chen, Feng (2018-12-01). "Developmental pathology of congenital kidney and urinary tract anomalies". Clinical Kidney Journal. 12 (3): 382–399. doi:10.1093/ckj/sfy112. ISSN 2048-8505. PMC 6543978. PMID 31198539.
- ^ Arnold, Georgianne L. (2018). "Inborn errors of metabolism in the 21st century: past to present". Annals of Translational Medicine. 6 (24): 467. doi:10.21037/atm.2018.11.36. ISSN 2305-5839. PMC 6331363. PMID 30740398.
- ^ Jones K, Smith D (1975). "The fetal alcohol syndrome". Teratology. 12 (1): 1–10. doi:10.1002/tera.1420120102. PMID 1162620.
- ^ Clarren S, Alvord E, Sumi S, Streissguth A, Smith D (1978). "Brain malformations related to prenatal exposure to ethanol". J Pediatr. 92 (1): 64–7. doi:10.1016/S0022-3476(78)80072-9. PMID 619080.
- ^ Abel EL, Sokol RJ (November 1986). "Fetal alcohol syndrome is now leading cause of mental retardation". Lancet. 2 (8517): 1222. doi:10.1016/s0140-6736(86)92234-8. PMID 2877359. S2CID 42708464.
- ^ Strömland K, Pinazo-Durán M (2002). "Ophthalmic involvement in the fetal alcohol syndrome: clinical and animal model studies". Alcohol Alcohol. 37 (1): 2–8. doi:10.1093/alcalc/37.1.2. PMID 11825849.
- ^ CDC (2025-01-30). "About Alcohol Use During Pregnancy". Alcohol and Pregnancy. Retrieved 2025-03-27.
- ^ May PA.; Gossage JP. (2001). "Estimating the prevalence of fetal alcohol syndrome. A summary". Alcohol Res Health. 25 (3): 159–67. PMC 6707173. PMID 11810953.
- ^ a b De Santis, Marco; Cesari, Elena; Cavaliere, Annafranca; Ligato, Maria Serena; Nobili, Elena; Visconti, Daniela; Caruso, Alessandro (September 2008). "Paternal exposure and counselling: Experience of a Teratology Information Service". Reproductive Toxicology. 26 (1): 42–46. Bibcode:2008RepTx..26...42D. doi:10.1016/j.reprotox.2008.06.003. PMID 18598753.
- ^ Hollander, Jessica; McNivens, Megan; Pautassi, Ricardo M.; Nizhnikov, Michael E. (2019). "Offspring of male rats exposed to binge alcohol exhibit heightened ethanol intake at infancy and alterations in T-maze performance". Alcohol. 76: 65–71. doi:10.1016/j.alcohol.2018.07.013. ISSN 0741-8329. PMC 6368891. PMID 30583252.
- ^ a b c d Trasler, Jacquetta M.; Doerksen, Tonia (September 1999). "Teratogen update: paternal exposures—reproductive risks". Teratology. 60 (3): 161–172. doi:10.1002/(SICI)1096-9926(199909)60:3<161::AID-TERA12>3.0.CO;2-A. PMID 10471901.
- ^ a b Abel, E. L. (2004). "Paternal contribution to fetal alcohol syndrome". Addiction Biology. 9 (2): 127–133. doi:10.1080/13556210410001716980. PMID 15223537. S2CID 22202776.
- ^ "Teratogens/Prenatal Substance Abuse". Understanding Genetics: A District of Columbia Guide for Patients and Health Professionals. Genetic Alliance; District of Columbia Department of Health. 2010-02-17. Archived from the original on 2019-12-20. Retrieved 2018-11-07.
- ^ van Gelder MM, van Rooij IA, Miller RK, Zielhuis GA, de Jong-van den Berg LT, Roeleveld N (January 2010). "Teratogenic mechanisms of medical drugs". Hum Reprod Update. 16 (4): 378–94. doi:10.1093/humupd/dmp052. hdl:2066/89039. PMID 20061329.
- ^ a b Ronan O'Rahilly; Fabiola Müller (2001). Human embryology & teratology. New York: Wiley-Liss. ISBN 978-0-471-38225-6.
- ^ a b c d e Zhu, J. L.; Madsen, K. M.; Vestergaard, M; Olesen, A. V.; Basso, O; Olsen, J (15 July 2005). "Paternal age and congenital malformations". Human Reproduction. 20 (11): 3173–3177. doi:10.1093/humrep/dei186. PMID 16006461.
- ^ a b c Ji, B.-T.; Shu, X.-O.; Zheng, W.; Ying, D.-M.; Linet, M. S.; Wacholder, S.; Gao, Y.-T.; Jin, F. (5 February 1997). "Paternal Cigarette Smoking and the Risk of Childhood Cancer Among Offspring of Nonsmoking Mothers". Journal of the National Cancer Institute. 89 (3): 238–243. doi:10.1093/jnci/89.3.238. PMID 9017004.
- ^ Bracken MB, Holford TR; Holford (1981). "Exposure to prescribed drugs in pregnancy and association with congenital malformations". Obstetrics and Gynecology. 58 (3): 336–44. PMID 7266953.
- ^ a b c d e Anderson, Diana; Schmid, ThomasE; Baumgartner, Adolf (2014). "Male-mediated developmental toxicity". Asian Journal of Andrology. 16 (1): 81–8. doi:10.4103/1008-682X.122342. PMC 3901885. PMID 24369136.
- ^ Chia, S-E; Shi, L. M. (1 March 2002). "Review of recent epidemiological studies on paternal occupations and birth defects". Occupational and Environmental Medicine. 59 (3): 149–155. doi:10.1136/oem.59.3.149. PMC 1763633. PMID 11886946.
- ^ King CR (1986). "Genetic counseling for teratogen exposure". Obstetrics and Gynecology. 67 (6): 843–6. doi:10.1097/00006250-198606000-00020. PMID 3703408.
- ^ Zurlinden, TJ; Saili, KS; Rush, N; Kothiya, P; Judson, RS; Houck, KA; Hunter, ES; Baker, NC; Palmer, JA; Thomas, RS; Knudson, TB (2020). "Profiling the ToxCast Library With a Pluripotent Human (H9) Stem Cell Line-Based Biomarker Assay for Developmental Toxicity". Toxicological Sciences. 174 (2): 189–209. doi:10.1093/toxsci/kfaa014. PMC 8527599. PMID 32073639.
- ^ a b c d e f g h i Peterka, Miroslav; Novotná, Božena (2010). Úvod do teratologie: příčiny a mechanizmy vzniku vrozených vad (1. vyd. ed.). Praha: Karolinum Press. ISBN 978-80-246-1780-0.
- ^ Hunt JR (1996). "Teratogenicity of high vitamin A intake". N. Engl. J. Med. 334 (18): 1197–1200. doi:10.1056/NEJM199605023341814. PMID 8602195.
- ^ Hartmann S, Brørs O, Bock J, et al. (2005). "Exposure to retinoic acids in non-pregnant women following high vitamin A intake with a liver meal". International Journal for Vitamin and Nutrition Research. 75 (3): 187–94. doi:10.1024/0300-9831.75.3.187. PMID 16028634.
- ^ "Search Jablonski's Syndromes Database". United States National Library of Medicine. Archived from the original on 2017-05-04. Retrieved 2016-04-07.
- ^ Manassaram, Deana M.; Backer, Lorraine C.; Moll, Deborah M. (2006). "A Review of Nitrates in Drinking Water: Maternal Exposure and Adverse Reproductive and Developmental Outcomes". Environmental Health Perspectives. 114 (3): 320–327. Bibcode:2006EnvHP.114..320M. doi:10.1289/ehp.8407. ISSN 0091-6765. PMC 1392223. PMID 16507452.
- ^ Croen, Lisa; Todoroff, Karen; Shaw, Gary (2001). "Maternal Exposure to Nitrate from Drinking Water and Diet and Risk for Neural Tube Defects". American Journal of Epidemiology. 153 (4): 325–31. doi:10.1093/aje/153.4.325. PMID 11207149.
- ^ Costas, K.; Knorr, R.S.; Condon, S.K. (2002). "A case-control study of childhood leukemia in Woburn, Massachusetts: the relationship between leukemia incidence and exposure to public drinking water". Science of the Total Environment. 300 (1–3): 23–35. Bibcode:2002ScTEn.300...23C. doi:10.1016/s0048-9697(02)00169-9. PMID 12685468.
- ^ In Harm's Way: Toxic Threats to Child Development (Report). Greater Boston Physicians for Social Responsibility. May 2000. pp. 90–2. Archived from the original on 24 September 2015. Retrieved 7 December 2014.
- ^ Delomenie, Myriam; Schneider, Floriane; Beaudet, Joëlle; Gabriel, René; Bednarek, Nathalie; Graesslin, Olivier (2015). "Carbon Monoxide Poisoning during Pregnancy: Presentation of a Rare Severe Case with Fetal Bladder Complications". Case Reports in Obstetrics and Gynecology. 2015 687975. doi:10.1155/2015/687975. ISSN 2090-6684. PMC 4365372. PMID 25834750.
- ^ Ritz, B.; Yu, F.; Fruin, S.; Chapa, G.; Shaw, G.; Harris, J. (2002). "Ambient Air Pollution and Risk of Birth Defects in Southern California" (PDF). American Journal of Epidemiology. 155 (1): 17–25. doi:10.1093/aje/155.1.17. PMID 11772780. Archived from the original (PDF) on 30 April 2015. Retrieved 7 December 2014.
- ^ Aubard, Yves; Magne, Isabelle (12 Aug 2005). "Carbon monoxide poisoning in pregnancy". British Journal of Obstetrics and Gynaecology. 107 (7): 833–8. doi:10.1111/j.1471-0528.2000.tb11078.x. PMC 2146365. PMID 10901551.
- ^ congenital defects
- ^ Griesbauer, Laura. "Methylmercury Contamination in Fish and Shellfish". CSA. CSA 2007. Archived from the original on 13 December 2014. Retrieved 7 December 2014.
- ^ Rushton, Lesley (2003). "Health hazards and waste management". British Medical Bulletin. 68 (1): 183–97. doi:10.1093/bmb/ldg034. PMID 14757717. S2CID 1500545.
- ^ Bullard, Robert. "Environmental Justice for All". National Humanities Center. Archived from the original on 29 March 2015. Retrieved 9 December 2014.
- ^ "Lead Poisoning". Mayo Clinic. Archived from the original on 21 December 2014. Retrieved 9 December 2014.
- ^ Berlac, Janne Foss; Hartwell, Dorthe; Skovlund, Charlotte Wessel; Langhoff-Roos, Jens; Lidegaard, Øjvind (June 2017). "Endometriosis increases the risk of obstetrical and neonatal complications". Acta Obstetricia et Gynecologica Scandinavica. 96 (6): 751–760. doi:10.1111/aogs.13111. PMID 28181672.
- ^ Arora, Nitin; Sadovsky, Yoel; Dermody, Terence S.; Coyne, Carolyn B. (2017). "Microbial Vertical Transmission during Human Pregnancy". Cell Host & Microbe. 21 (5): 561–567. doi:10.1016/j.chom.2017.04.007. ISSN 1931-3128. PMC 6148370. PMID 28494237.
- ^ Mawson, Anthony R.; Croft, Ashley M. (2019). "Rubella Virus Infection, the Congenital Rubella Syndrome, and the Link to Autism". International Journal of Environmental Research and Public Health. 16 (19): 3543. doi:10.3390/ijerph16193543. ISSN 1660-4601. PMC 6801530. PMID 31546693.
- ^ a b c d e f Sadler, T.W. (1985). Langman's Medical Embryology (5th ed.). Baltimore: William & Wilkins. pp. 109–12. ISBN 978-0-683-07490-1.
- ^ "Microcephaly". Mayo Clinic. Archived from the original on 21 December 2014. Retrieved 7 December 2014.
- ^ "Cerebral calcification, nonarteriosclerotic". MedicineNet.com. Archived from the original on 3 July 2015. Retrieved 7 December 2014.
- ^ "Hepatosplenomegaly-Symptoms, Causes, Treatment". Symptoms and Treatment RSS. 22 August 2011. Archived from the original on 10 November 2014. Retrieved 7 December 2014.
- ^ "Kernicterus". MedlinePlus Medical Encyclopedia. Archived from the original on 5 January 2015. Retrieved 7 December 2014.
- ^ "Petechiae". Mayo Clinic. Archived from the original on 22 April 2015. Retrieved 7 December 2014.
- ^ "Microphthalmus". Texas School for the Blind and Visually Impaired. Archived from the original on 17 November 2014. Retrieved 7 December 2014.
- ^ "Facts about Anencephaly". Centers for Disease Control and Prevention. Archived from the original on 10 December 2014. Retrieved 7 December 2014.
- ^ "Hydrocephalus". Mayo Clinic. Archived from the original on 24 December 2014. Retrieved 7 December 2014.
- ^ a b Raats, Monique (1998). Changing Preconceptions. London: Health Education Authority. p. 11. ISBN 978-0-7521-1231-2.
- ^ Anderson, Lucy M.; Riffle, Lisa; Wilson, Ralph; Travlos, Gregory S.; Lubomirski, Mariusz S.; Alvord, W. Gregory (March 2006). "Preconceptional fasting of fathers alters serum glucose in offspring of mice". Nutrition. 22 (3): 327–331. doi:10.1016/j.nut.2005.09.006. PMID 16500559. Archived from the original on 2020-07-27. Retrieved 2019-09-12.
- ^ Bhandari, Jenish; Thada, Pawan K.; Sergent, Shane R. (2022), "Potter Syndrome", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32809693, archived from the original on 2023-03-16, retrieved 2022-10-31
- ^ Rahbaran, Mohaddeseh; Razeghian, Ehsan; Maashi, Marwah Suliman; Jalil, Abduladheem Turki; Widjaja, Gunawan; Thangavelu, Lakshmi; Kuznetsova, Mariya Yurievna; Nasirmoghadas, Pourya; Heidari, Farid; Marofi, Faroogh; Jarahian, Mostafa (2021-11-30). "Cloning and Embryo Splitting in Mammalians: Brief History, Methods, and Achievements". Stem Cells International. 2021 2347506. doi:10.1155/2021/2347506. ISSN 1687-966X. PMC 8651392. PMID 34887927.
- ^ a b c d e f Sartorius, G. A.; Nieschlag, E. (20 August 2009). "Paternal age and reproduction". Human Reproduction Update. 16 (1): 65–79. doi:10.1093/humupd/dmp027. PMID 19696093.
- ^ a b Savitz, David A.; Schwingl, Pamela J.; Keels, Martha Ann (October 1991). "Influence of paternal age, smoking, and alcohol consumption on congenital anomalies". Teratology. 44 (4): 429–440. doi:10.1002/tera.1420440409. PMID 1962288.
- ^ Avidor-Reiss, T.; Mazur, M.; Fishman, E. L.; Sindhwani, P. (2019). "The Role of Sperm Centrioles in Human Reproduction – The Known and the Unknown - PMC". Frontiers in Cell and Developmental Biology. 7 188. doi:10.3389/fcell.2019.00188. PMC 6781795. PMID 31632960.
- ^ "Men may contribute to infertility through newly discovered part of sperm | UToledo News". June 7, 2018. Archived from the original on January 8, 2023. Retrieved January 8, 2023.
- ^ a b c de Graaf, Johanna P.; Steegers, Eric A.P.; Bonsel, Gouke J. (April 2013). "Inequalities in perinatal and maternal health". Current Opinion in Obstetrics and Gynecology. 25 (2): 98–108. doi:10.1097/GCO.0b013e32835ec9b0. PMID 23425665. S2CID 41767750.
- ^ a b c d Vos, Amber A.; Posthumus, Anke G.; Bonsel, Gouke J.; Steegers, Eric A.P.; Denktaş, Semiha (August 2014). "Deprived neighborhoods and adverse perinatal outcome: a systematic review and meta-analysis". Acta Obstetricia et Gynecologica Scandinavica. 93 (8): 727–740. doi:10.1111/aogs.12430. hdl:1765/68911. PMID 24834960. S2CID 39860659.
- ^ a b c Bradley, Robert H.; Corwyn, Robert F. (February 2002). "S S C D". Annual Review of Psychology. 53 (1): 371–399. doi:10.1146/annurev.psych.53.100901.135233. PMID 11752490. S2CID 43766257.
- ^ Health risk assessment from the nuclear accident after the 2011 Great East Japan Earthquake and Tsunami based on a preliminary dose estimation (PDF). World Health Organization. 2013. pp. 23–24. ISBN 978-92-4-150513-0. Archived (PDF) from the original on 2017-12-15. Retrieved 2013-11-21.
- ^ Heath, Clark W. (1992). "The Children of Atomic Bomb Survivors: A Genetic Study". JAMA: The Journal of the American Medical Association. 268 (5): 633–634. Bibcode:1992RadR..131..229A. doi:10.1001/jama.1992.03490050109039. PMC 1682172.
No differences were found (in frequencies of birth defects, stillbirths, etc), thus allaying the immediate public concern that atomic radiation might spawn an epidemic of malformed children
- ^ Kalter, Harold (2010). Teratology in the Twentieth Century Plus Ten. Springer Netherlands. p. 21. ISBN 978-90-481-8820-8. Retrieved 28 October 2014.
- ^ Winther, J F; Boice, J D; Thomsen, B L; Schull, W J; Stovall, M; j h Olsen (2003). "Sex ratio among offspring of childhood cancer survivors treated with radiotherapy". British Journal of Cancer. 88 (3): 382–7. doi:10.1038/sj.bjc.6600748. PMC 2747537. PMID 12569380.
- ^ "Birth defects among the children of atomic-bomb survivors (1948–1954)". RERF.jp. Radiation Effects Research Foundation. Archived from the original on 2018-05-20. Retrieved 2013-11-21.
- ^ Voosen, Paul (11 April 2011). "Nuclear crisis: Hiroshima and Nagasaki cast long shadows over radiation science". E&E News. Archived from the original on 5 April 2012. Retrieved 28 October 2014.
- ^ Dubrova, Yuri E.; Nesterov, Valeri N.; Krouchinsky, Nicolay G.; Ostapenko, Valdislav A.; Neumann, Rita; Neil, David L.; Jeffreys, Alec J. (25 April 1996). "Human minisatellite mutation rate after the Chernobyl accident". Nature. 380 (6576): 683–686. Bibcode:1996Natur.380..683D. doi:10.1038/380683a0. PMID 8614461. S2CID 4303433.
- ^ Bennett, Burton; Repacholi, Michael; Carr, Zhanat, eds. (2006). Health Effects of the Chernobyl Accident and Special Health Care Programmes: Report of the UN Chernobyl Forum, Expert Group "Health" (PDF). Geneva: World Health Organization (WHO). p. 79. ISBN 978-92-4-159417-2. Archived (PDF) from the original on 12 August 2011. Retrieved 20 August 2011.
- ^ Furitsu Katsumi (2005). "Microsatellite mutations show no increases in the children of the Chernobyl liquidators". Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 581 (1–2): 69–82. Bibcode:2005MRGTE.581...69F. doi:10.1016/j.mrgentox.2004.11.002. PMID 15725606.
- ^ Dickinson HO, Parker L (1999). "Quantifying the effect of population mixing on childhood leukaemia risk: the Seascale cluster". British Journal of Cancer. 81 (1): 144–151 [146, 149]. doi:10.1038/sj.bjc.6690664. PMC 2374359. PMID 10487626.
- ^ Lean, Samantha C.; Derricott, Hayley; Jones, Rebecca L.; Heazell, Alexander E. P. (2017-10-17). "Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis". PLOS ONE. 12 (10) e0186287. Bibcode:2017PLoSO..1286287L. doi:10.1371/journal.pone.0186287. ISSN 1932-6203. PMC 5645107. PMID 29040334.
- ^ a b Olshan, Andrew F.; Schnitzer, Patricia G.; Baird, Patricia A. (July 1994). "Paternal age and the risk of congenital heart defects". Teratology. 50 (1): 80–84. doi:10.1002/tera.1420500111. PMID 7974258.
- ^ Yang, Q.; Wen, S.W.; Leader, A.; Chen, X.K.; Lipson, J.; Walker, M. (7 December 2006). "Paternal age and birth defects: how strong is the association?". Human Reproduction. 22 (3): 696–701. doi:10.1093/humrep/del453. PMID 17164268.
- ^ Wiener-Megnazi, Zofnat; Auslender, Ron; Dirnfeld, Martha (12 December 2011). "Advanced paternal age and reproductive outcome". Asian Journal of Andrology. 14 (1): 69–76. doi:10.1038/aja.2011.69. PMC 3735149. PMID 22157982.
- ^ Bezerra Guimarães MJ, Marques NM, Melo Filho DA (2000). "Taux de mortalité infantile et disparités sociales à Recife, métropole du Nord-Est du Brésil" [Infant mortality rate and social disparity at Recife, the metropolis of the North-East of Brazil]. Santé (in French). 10 (2): 117–21. PMID 10960809. Archived from the original on 2021-08-28. Retrieved 2013-11-10.
- ^ Kumar, Abbas and Fausto, eds., Robbins and Cotran's Pathologic Basis of Disease, 7th edition, p.473.
- ^ Miniard L., Nichols C., Smith J., Jarrin-Yepez P., Grzeskowiak R., & Newkirk K. (2023). Schistosomus reflexus with another fetus in a beef heifer. Clinical Theriogenology, 15. https://doi.org/10.58292/ct.v15.9609
- ^ Chen, J; Gong, X; Chen, P; Luo, K; Zhang, X (16 August 2016). "Effect of L-arginine and sildenafil citrate on intrauterine growth restriction fetuses: a meta-analysis". BMC Pregnancy and Childbirth. 16 225. doi:10.1186/s12884-016-1009-6. PMC 4986189. PMID 27528012.
- ^ Simonsen, H (25 November 2002). "[Screening of newborns for inborn errors of metabolism by tandem mass spectrometry]". Ugeskrift for Laeger. 164 (48): 5607–12. PMID 12523003.
- ^ a b c Wilcken, B; Wiley, V (February 2008). "Newborn screening". Pathology. 40 (2): 104–15. doi:10.1080/00313020701813743. PMID 18203033.
- ^ Ezgu, F (2016). Inborn Errors of Metabolism. Vol. 73. pp. 195–250. doi:10.1016/bs.acc.2015.12.001. ISBN 978-0-12-804690-6. PMID 26975974.
{{cite book}}:|journal=ignored (help) - ^ "Newborn screening for DMD shows promise as an international model". Nationwide Children's Hospital. 2012-03-19. Archived from the original on 2015-10-15. Retrieved 2018-04-02.
- ^ "WHO Disease and injury country estimates". World Health Organization. 2009. Archived from the original on November 11, 2009. Retrieved Nov 11, 2009.
- ^ Gittelsohn, A; Milham, S (1964). "Statistical Study of Twins—Methods". American Journal of Public Health and the Nation's Health. 54 (2): 286–294. doi:10.2105/ajph.54.2.286. PMC 1254713. PMID 14115496.
- ^ Fernando, J; Arena, P; Smith, D. W. (1978). "Sex liability to single structural defects". American Journal of Diseases of Children. 132 (10): 970–972. doi:10.1001/archpedi.1978.02120350034004. PMID 717306.
- ^ Lubinsky, M. S. (1997). "Classifying sex biased congenital anomalies". American Journal of Medical Genetics. 69 (3): 225–228. doi:10.1002/(SICI)1096-8628(19970331)69:3<225::AID-AJMG1>3.0.CO;2-K. PMID 9096746.
- ^ Lary, J. M.; Paulozzi, L. J. (2001). "Sex differences in the prevalence of human birth defects: A population-based study". Teratology. 64 (5): 237–251. doi:10.1002/tera.1070. PMID 11745830.
- ^ a b c d e f Cui, W; Ma, C. X.; Tang, Y; Chang, V; Rao, P. V.; Ariet, M; Resnick, M. B.; Roth, J (2005). "Sex differences in birth defects: A study of opposite-sex twins". Birth Defects Research Part A: Clinical and Molecular Teratology. 73 (11): 876–880. doi:10.1002/bdra.20196. PMID 16265641.
- ^ a b World Health Organization reports. "Congenital malformations", Geneve, 1966, p. 128.
- ^ Darwin C. (1871) The descent of man and selection in relation to sex. London, John Murray, 1st ed.
- ^ "Diagnosis | Birth Defects | NCBDDD | CDC". Centers for Disease Control and Prevention. 2017-12-04. Archived from the original on 2018-11-07. Retrieved 2018-11-07.
- ^ Kumar, Abbas and Fausto, eds., Robbins and Cotran's Pathologic Basis of Disease, 7th edition, p.470.
- ^ Dicke JM (1989). "Teratology: principles and practice". Med. Clin. North Am. 73 (3): 567–82. doi:10.1016/S0025-7125(16)30658-7. PMID 2468064.
- ^ a b c d e f g h i j k l m n o p q r Rajewski P. M., Sherman A. L. (1976) The importance of gender in the epidemiology of malignant tumors (systemic-evolutionary approach). In: Mathematical treatment of medical-biological information. M., Nauka, p. 170–181.
- ^ a b c d Montagu A. (1968) Natural Superiority of Women, The, Altamira Press, 1999.
- ^ a b c d e f g h i Riley M., Halliday J. (2002) Birth Defects in Victoria 1999–2000, Melbourne.
- ^ Shaw, G. M.; Carmichael, S. L.; Kaidarova, Z; Harris, J. A. (2003). "Differential risks to males and females for congenital malformations among 2.5 million California births, 1989–1997". Birth Defects Research Part A: Clinical and Molecular Teratology. 67 (12): 953–958. doi:10.1002/bdra.10129. PMID 14745913.
- ^ Reyes, F. I.; Boroditsky, R. S.; Winter, J. S.; Faiman, C (1974). "Studies on human sexual development. II. Fetal and maternal serum gonadotropin and sex steroid concentrations". The Journal of Clinical Endocrinology & Metabolism. 38 (4): 612–617. doi:10.1210/jcem-38-4-612. PMID 4856555.
- ^ Mdforlives (2021-01-31). "Birth Defects: Saving Pediatric Patients from Congenital Defects". MDforLives. Archived from the original on 2021-02-13. Retrieved 2021-02-09.
- ^ "Key Findings: Updated National Birth Prevalence Estimates for Selected Birth Defects in the United States, 2004–2006". CDC. Centers for Disease Control and Prevention (CDC) and the National Birth Defects Prevention Network. Archived from the original on October 28, 2014. Retrieved October 1, 2014.
External links
[edit]Birth defect
View on GrokipediaDefinition and Classification
Definition
A birth defect, also termed a congenital anomaly, refers to any structural or functional abnormality originating during embryonic or fetal development and evident at birth. These anomalies encompass malformations in body structure, such as cardiac septal defects or neural tube defects like spina bifida, as well as disruptions in physiological processes, including metabolic disorders like congenital hypothyroidism.[1][4][9] Such conditions arise from aberrant processes in intrauterine life, potentially involving genetic mutations, environmental teratogens, or unknown etiologies, and may range from minor variations with negligible impact to major defects requiring medical intervention, surgery, or lifelong management.[10][11] The term "birth defect" prioritizes descriptive accuracy over euphemistic alternatives, reflecting observable deviations from typical human morphology and function established through empirical observation and clinical diagnostics.[12] Globally, these anomalies affect approximately 3-6% of live births, underscoring their prevalence as a leading contributor to infant morbidity and mortality, though precise incidence varies by diagnostic criteria and population studied.[4][13]Structural Defects
Structural defects, also known as structural congenital anomalies, refer to abnormalities in the physical form or architecture of body organs, limbs, or other parts present at birth. These defects originate from disruptions in embryonic or fetal morphogenesis and are classified into malformations (defective formation of tissues), deformations (abnormal shape due to extrinsic mechanical forces like uterine constraint), and disruptions (secondary destruction of otherwise normal structures).[14][15] Common examples include congenital heart defects, such as ventricular septal defects or tetralogy of Fallot; neural tube defects like spina bifida and anencephaly; orofacial clefts (cleft lip with or without cleft palate); limb reduction defects; abdominal wall defects (gastroschisis and omphalocele); and genitourinary anomalies like hypospadias.[16][15][4] Congenital heart defects represent the most prevalent structural anomalies, occurring in approximately 8-12 per 1,000 live births globally, while neural tube defects affect about 1-5 per 1,000 births depending on folic acid fortification status.[1][16] Major structural defects occur in roughly 3% of live births in the United States, contributing to about 20% of infant mortality and significant long-term morbidity, including surgical interventions and developmental challenges.[1][14] Worldwide, structural anomalies account for a substantial portion of the estimated 6% of newborns with congenital disorders, with higher burdens in low-resource settings due to limited prenatal screening and folic acid supplementation.[4][17] These defects are often detectable via prenatal ultrasound, enabling early intervention, though many remain idiopathic despite advances in imaging and genetic testing.[18]Functional and Metabolic Defects
Functional defects comprise congenital anomalies that disrupt the physiological performance of body systems, including neurological, endocrine, and immune functions, typically without accompanying gross structural malformations visible at birth. These impairments manifest as abnormalities in biochemical signaling, hormone regulation, or neural processing, often requiring specialized diagnostic tests beyond routine imaging to identify.[19][4] Metabolic defects form a core subset of functional anomalies, primarily consisting of inborn errors of metabolism (IEMs) arising from monogenic mutations that impair enzymes, cofactors, or transporters essential for catabolic or anabolic pathways. Such disruptions cause substrate buildup, product shortages, or toxic intermediates, leading to multisystem effects like acidosis, hypoglycemia, or neurodegeneration if not addressed promptly.[20][21] Collectively, IEMs affect 1 in 1,500 to 2,500 live births worldwide, with individual incidences varying widely due to population genetics and screening efficacy.[22][20] Prominent examples include phenylketonuria (PKU), an autosomal recessive disorder from phenylalanine hydroxylase deficiency, resulting in hyperphenylalaninemia and potential intellectual impairment from neurotoxic effects; its incidence stands at roughly 1 in 10,000 to 15,000 U.S. births, higher among Caucasians.[23][24] Other IEM categories encompass amino acidopathies (e.g., maple syrup urine disease, incidence ~1:185,000), organic acidemias (e.g., propionic acidemia, ~1:100,000), and urea cycle disorders (e.g., ornithine transcarbamylase deficiency, ~1:14,000 males).[21] Lysosomal storage disorders, such as Tay-Sachs disease (hexosaminidase A deficiency causing GM2 ganglioside accumulation), exemplify neurodegenerative metabolic defects, with incidence ~1:3,600 among Ashkenazi Jews but far rarer globally (~1:320,000).[25][21] Endocrine functional defects, like congenital hypothyroidism from thyroid hormone synthesis defects or dysgenesis, impair growth and cognition; incidence approximates 1:2,000 to 4,000 births, mitigated by levothyroxine replacement post-screening.[26] Congenital adrenal hyperplasia due to 21-hydroxylase deficiency disrupts steroidogenesis, causing salt-wasting crises or virilization; prevalence ~1:15,000.[21] Diagnosis of these defects relies heavily on newborn screening via tandem mass spectrometry and immunoassays, enabling presymptomatic intervention to avert irreversible damage, though not all IEMs are screened universally.[20] Genetic confirmation via sequencing follows initial positives, underscoring the heritability of most cases.[22]Chromosomal and Genetic Anomalies
Chromosomal anomalies involve alterations in the number or structure of chromosomes, which carry genetic information, and account for approximately 5 per 1,000 live births.[27] These defects often arise from errors during cell division in gamete formation or early embryonic development, leading to conditions such as aneuploidy, where there is an abnormal number of chromosomes, or structural changes like deletions, duplications, inversions, or translocations. Aneuploidy, the most common type, includes trisomies—extra copies of a chromosome—and monosomies—missing chromosomes. Trisomy 21, known as Down syndrome, exemplifies this, with an extra chromosome 21 resulting in intellectual disability, characteristic facial features, and increased risk of congenital heart defects; its prevalence is about 1 in 700 live births in the United States.[28][29] Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) are rarer, occurring in roughly 1 in 5,000 and 1 in 16,000 live births, respectively, and are associated with severe multiple organ malformations and high infant mortality rates exceeding 90% in the first year.[30] Sex chromosome anomalies, such as Turner syndrome (45,X monosomy, affecting 1 in 2,000 to 2,500 female births), cause short stature, ovarian dysgenesis, and cardiac anomalies, while Klinefelter syndrome (47,XXY, in 1 in 500 to 1,000 male births) leads to hypogonadism and learning difficulties.[31] Structural anomalies, like the 5p deletion in cri-du-chat syndrome (prevalence around 1 in 50,000 births), produce a high-pitched cry, microcephaly, and developmental delays due to loss of genetic material on chromosome 5's short arm.[32] Genetic anomalies, distinct from chromosomal ones, primarily stem from mutations in single genes or small segments of DNA, rather than whole chromosomes, and contribute to about 20% of birth defects through inherited or de novo changes.[33] These follow Mendelian inheritance patterns: autosomal recessive disorders require two mutated alleles, one from each parent, as in cystic fibrosis caused by CFTR gene mutations, with carrier frequency highest in Europeans (1 in 25) and birth prevalence of 1 in 2,500 to 3,500 affected infants exhibiting respiratory and pancreatic issues from birth.[34] Autosomal dominant conditions need only one mutated allele, such as achondroplasia from FGFR3 mutations, the most common form of dwarfism with an incidence of 1 in 15,000 to 40,000 births, featuring disproportionate short limbs and normal intelligence.[31] X-linked disorders disproportionately affect males due to hemizygosity; Duchenne muscular dystrophy, from dystrophin gene mutations, has a prevalence of 1 in 3,500 to 5,000 male births, manifesting as progressive muscle weakness evident by age 3-5.[34] De novo mutations, not inherited, drive some cases, like Noonan syndrome from RAS pathway genes, which presents with congenital heart defects and short stature in about 1 in 1,000 to 2,500 births. Non-Mendelian mechanisms, including genomic imprinting (e.g., Prader-Willi vs. Angelman syndromes depending on parental origin of chromosome 15 deletion) and trinucleotide repeats (e.g., fragile X syndrome, the leading inherited intellectual disability cause at 1 in 4,000 males), further diversify genetic anomalies.[35] Overall, while chromosomal anomalies are detectable via karyotyping and often linked to advanced maternal age, genetic ones require targeted sequencing and show variable penetrance influenced by allele dosage and modifiers.[36]Etiology
Genetic Mechanisms
Birth defects arise from diverse genetic mechanisms, primarily involving disruptions in chromosomal structure or number, mutations in single genes, and epigenetic modifications such as genomic imprinting. Chromosomal abnormalities, which include aneuploidies, deletions, duplications, and translocations, account for approximately 10-15% of major congenital anomalies diagnosed in the first year of life.[37] These errors typically occur during meiosis in gametogenesis or early embryonic mitosis, leading to imbalances in genetic material that impair embryonic development. For example, trisomy 21 (Down syndrome), resulting from nondisjunction, manifests in structural defects like atrioventricular septal defects and intellectual disability, with a live birth prevalence of about 1 in 700 infants.[4] Aneuploidies such as trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) are similarly lethal or severely debilitating, often involving multiple organ systems due to gene dosage effects disrupting developmental signaling pathways.[4] Single-gene disorders, caused by pathogenic variants in protein-coding sequences, follow Mendelian inheritance patterns and represent roughly 20-25% of genetically attributable birth defects.[38] Autosomal dominant conditions, such as achondroplasia from FGFR3 gain-of-function mutations, exhibit incomplete penetrance and variable expressivity, arising either through inheritance or de novo events in spermatogenesis, which increase with advanced paternal age.[39] Autosomal recessive disorders, like cystic fibrosis due to CFTR mutations, require biallelic inheritance and often present with functional defects such as respiratory and pancreatic insufficiency, with carrier frequencies varying by population (e.g., 1 in 25 among Europeans).[40] X-linked recessive patterns predominate in hemophilia A (F8 gene inversions) and Duchenne muscular dystrophy (DMD deletions), disproportionately affecting males due to hemizygosity, while X-linked dominant conditions like incontinentia pigmenti involve skewed X-inactivation. De novo mutations, absent in parental genomes, drive up to 1-2% recurrence risk in subsequent siblings for dominant disorders and are enriched in sperm-derived variants, contributing to sporadic structural anomalies like congenital diaphragmatic hernia.[41][42] Beyond Mendelian and chromosomal etiologies, submicroscopic genomic alterations such as copy number variations (CNVs) and mosaicism underlie additional cases, often escaping standard karyotyping. CNVs, involving deletions or duplications of DNA segments larger than 1 kb, disrupt dosage-sensitive genes critical for organogenesis, as seen in 22q11.2 deletion syndrome (DiGeorge/velocardiofacial syndrome), which affects conotruncal heart defects and thymic hypoplasia in about 1 in 4,000 births.[43] Mosaicism, where mutant cells coexist with normal ones post-zygotically, can produce segmental defects like linear skin lesions in proteus syndrome from mosaic AKT1 activation. Genomic imprinting disorders, characterized by parent-of-origin-specific gene silencing via DNA methylation, cause growth and neurodevelopmental anomalies; for instance, Prader-Willi syndrome results from paternal loss of 15q11.2-q13 expression (deletion or uniparental disomy), while maternal loss at the same locus yields Angelman syndrome with severe intellectual disability and seizures.[44] These mechanisms highlight the interplay of mutational timing, genomic context, and parental contributions in congenital pathogenesis.[36]Environmental Exposures
Certain pharmaceuticals qualify as teratogens when exposure occurs during critical windows of fetal development. Thalidomide, prescribed in the late 1950s and early 1960s for morning sickness, caused severe limb reduction defects (phocomelia) in thousands of infants when taken between days 20 and 36 post-conception, with an estimated 10,000-20,000 affected cases worldwide before its withdrawal in 1961.[45] Similarly, anticonvulsants like valproic acid, used for epilepsy, elevate risks of neural tube defects and cardiac anomalies by up to 10-20 times when ingested in the first trimester, based on cohort studies tracking exposed pregnancies.[46] Maternal alcohol consumption during pregnancy induces fetal alcohol spectrum disorders (FASD), encompassing craniofacial dysmorphology, growth deficits, and central nervous system impairments, with prevalence estimates of 1-5% in general populations and higher in heavy drinkers; no safe threshold exists, as even low doses correlate with subtle neurobehavioral effects in prospective studies.[47] Tobacco smoking exposes the fetus to nicotine, carbon monoxide, and polycyclic aromatic hydrocarbons via placental transfer, increasing odds of orofacial clefts by 1.3-fold and congenital heart defects by 1.1-1.5-fold, per meta-analyses of over 10,000 cases, with risks dose-dependent on cigarettes per day.[48] Ionizing radiation, such as from diagnostic X-rays or therapeutic exposures, disrupts DNA replication in rapidly dividing fetal cells, particularly between weeks 2-8 gestation, leading to microcephaly, eye malformations, and intellectual disability; atomic bomb survivor data indicate a 40-50% excess risk of severe defects per 1 Gy absorbed dose to the embryo.[49] Maternal infections act as environmental teratogens by triggering inflammation or direct viral invasion; rubella virus in the first trimester causes congenital rubella syndrome in up to 90% of cases, featuring cataracts, deafness, and heart defects, while Zika virus exposure links to microcephaly via neuronal apoptosis, with outbreak data from 2015-2016 showing 5-15% affected fetuses in infected pregnancies.[4] Ambient pollutants, including heavy metals and pesticides, contribute modestly to defects through oxidative stress and epigenetic disruption. Prenatal exposure to lead (Pb), cadmium (Cd), arsenic (As), and mercury (Hg) raises neural tube defect odds by 1.5-3-fold in case-control studies from contaminated regions, with blood levels above 5 μg/dL correlating to impaired closure; however, causation requires high doses, as low-level urban exposures show inconsistent effects.[50] Pesticides like organophosphates and glyphosate have limited human evidence, with some cohort data suggesting 1.2-2-fold increased risks for limb and genital defects in agricultural workers' offspring, though confounding by lifestyle factors persists and regulatory reviews deem most non-teratogenic at environmental doses.[51] Overall, environmental teratogens account for about 10% of structural birth defects, often requiring gene-environment interactions for manifestation, as isolated exposures rarely suffice in isolation.[52][53]Gene-Environment Interactions
Gene-environment interactions contribute substantially to the multifactorial etiology of birth defects, particularly non-syndromic structural anomalies, where genetic variants influence individual susceptibility to environmental exposures during critical developmental windows. These interactions often involve polymorphisms in genes related to metabolism, detoxification, or signaling pathways that alter responses to teratogens such as nutritional deficiencies, toxins, or maternal metabolic states. Empirical studies, including case-control analyses and animal models, demonstrate that neither genetic factors nor environmental insults alone suffice for many defects; instead, their synergy determines penetrance and severity. For example, in neural tube defects (NTDs), variants in the MTHFR gene, such as the 677C>T polymorphism, reduce enzyme activity by up to 70%, impairing folate conversion and elevating homocysteine levels, which correlates with a 1.5- to 2-fold increased NTD risk in low-folate environments, though supplementation with 400-800 mcg daily folic acid mitigates this by normalizing folate status even in homozygous carriers.[54][55] Orofacial clefts, including cleft lip with or without palate (CL/P), exemplify interactions with maternal smoking: exposure to tobacco smoke increases CL/P odds by 1.2- to 1.5-fold overall, but this risk amplifies 2- to 10-fold in infants with null genotypes in glutathione S-transferase genes (GSTT1 or GSTM1), which encode enzymes detoxifying polycyclic aromatic hydrocarbons and nitrosamines from cigarettes; similarly, variants in IRF6 (e.g., rs2235371) interact with smoking to heighten penetrance via disrupted craniofacial signaling.[56][57][58] These findings stem from large cohort studies, though confounding by unmeasured factors like passive smoke or diet persists, underscoring the need for genome-wide approaches to disentangle causality.[59] In congenital heart defects (CHDs), gene-environment interplay involves variants in folate pathway genes (e.g., MTHFR) combined with periconceptional exposures like air pollution or anticonvulsants; for instance, maternal valproic acid use during early pregnancy raises CHD risk 2- to 3-fold, potentiated by embryonic polymorphisms in histone deacetylase genes that impair neural crest migration.[60][61] Maternal phenylketonuria illustrates a classic dietary interaction: unchecked hyperphenylalaninemia (>360 μmol/L) from PAH gene mutations causes microcephaly and cardiac anomalies in 10-20% of offspring via oxidative stress on fetal development, preventable by strict preconception phenylalanine restriction to <120 μmol/L.[62] Detecting such interactions remains challenging due to small effect sizes, rare exposures in early gestation, and ethical limits on human trials, with animal models confirming mechanisms like altered DNA methylation or Hedgehog signaling disruption.[63][64] Overall, these examples highlight how modifiable environmental factors can exploit genetic vulnerabilities, informing targeted prevention over broad interventions.[65]Idiopathic Cases
A substantial proportion of birth defects are classified as idiopathic, meaning their etiology remains unknown despite comprehensive clinical and genetic evaluation. Estimates indicate that 50% to 70% of congenital anomalies fall into this category, with some analyses reporting figures as high as nearly 80% where no specific cause can be identified.[33][66] This classification arises from the absence of detectable chromosomal abnormalities, single-gene mutations, or confirmed environmental teratogens, though it does not preclude underlying causal mechanisms such as undetected multifactorial interactions.[67] The predominance of idiopathic cases underscores gaps in current etiological understanding, particularly for structural defects like isolated cleft palate or congenital heart anomalies without syndromic features. Routine diagnostic tools, including karyotyping and targeted sequencing, identify causes in only 20% to 50% of instances, leaving the remainder attributed to idiopathic origins.[68] Advances in whole-genome sequencing have begun reclassifying some previously idiopathic cases by revealing de novo variants or polygenic risks, yet the majority persist without explanation due to the complexity of embryonic development and subtle prenatal influences.[69] From a causal perspective, idiopathic designations likely mask intricate gene-environment interplay or stochastic developmental errors not yet resolvable by empirical methods. For instance, in non-syndromic clubfoot (talipes equinovarus), which affects approximately 1 in 1,000 live births, multifactorial genesis involving genetic predisposition and unidentified environmental triggers is hypothesized, but specific etiologies elude identification in most cases.[70] Similarly, up to 50% of congenital anomalies may involve undetected combinations of genetic susceptibility and non-obvious exposures, highlighting the need for longitudinal studies to diminish the idiopathic fraction through refined causal inference.[67] Ongoing genomic research, including large-scale cohort analyses, aims to parse these cases, but empirical data affirm that unknown etiologies remain the norm rather than exception in birth defect epidemiology.[71]Risk Factors
Parental Age and Reproductive Choices
Advanced maternal age, typically defined as 35 years or older, is a well-established risk factor for chromosomal birth defects, particularly aneuploidies such as trisomy 21 (Down syndrome) and trisomy 18. The risk of Down syndrome rises exponentially with maternal age: approximately 1 in 1,250 live births for mothers aged 25 years, increasing to 1 in 100 for those aged 40 years and 1 in 30 for those aged 45 years.[72] Each additional year of maternal age beyond 35 is associated with a 1.177-fold increase in trisomy 21 risk and a 1.182-fold increase in trisomy 18 risk, attributable to age-related declines in oocyte quality and meiotic error rates.[73] These associations hold after controlling for confounding factors like socioeconomic status, though some studies note stronger links for trisomy 18 than trisomy 13.[74] Advanced paternal age, generally above 40-45 years, correlates with elevated risks of certain non-chromosomal birth defects and de novo mutations, including urogenital anomalies, cardiovascular malformations, facial clefts, and increased incidence of disorders like autism spectrum conditions and schizophrenia in offspring.[75] A systematic review of population-based studies found paternal age independently associated with higher odds of these defects, potentially due to accumulated germline mutations from ongoing spermatogenesis and DNA repair inefficiencies.[76] Unlike maternal effects, paternal age risks persist even after adjusting for maternal age and do not show the same exponential chromosomal pattern but contribute to sporadic genetic anomalies.[39] Reproductive choices such as delayed childbearing exacerbate these age-related risks by shifting parenthood to later ages, with population trends showing rising average maternal age linked to higher rates of preterm birth, low birth weight, and congenital anomalies.[77] Assisted reproductive technologies (ART), including in vitro fertilization (IVF), further elevate defect risks by 20-40% overall compared to natural conception, with odds ratios of 1.22 for any major birth defect and up to 36% higher for congenital heart defects, though some evidence suggests frozen embryo transfers may mitigate this.[78][79] These elevations may stem from procedural factors like embryo manipulation or underlying parental infertility, rather than age alone, underscoring the need for pre-conception counseling on trade-offs between fertility preservation and fetal health.[80]Maternal Behaviors and Lifestyle
Maternal smoking during pregnancy is associated with increased risks of congenital anomalies, including oral clefts, congenital heart defects, and urogenital malformations. A systematic review of epidemiological studies found that smoking elevates the odds of cleft lip and palate by approximately 1.3-fold, with stronger associations in active smokers compared to passive exposure.[81] Mechanisms may involve nicotine-induced vasoconstriction and hypoxia affecting fetal development, though confounding by socioeconomic factors persists in observational data.[82] Alcohol consumption in pregnancy acts as a teratogen, linked to fetal alcohol spectrum disorders that include structural birth defects such as cardiac septal defects and craniofacial anomalies. Cohort studies indicate that even low-to-moderate intake raises malformation risks, with binge drinking showing dose-dependent effects on midline defects.[83] While some analyses report null associations for specific defects like clefts, meta-analyses affirm overall teratogenicity, independent of confounders like nutrition.[84][85] Illicit drug use, including cocaine, opioids, and methamphetamine, correlates with adverse fetal outcomes beyond growth restriction, encompassing genitourinary and limb defects. Prenatal cocaine exposure heightens risks of urinary tract anomalies via vascular disruption, with population studies reporting up to twofold elevations in specific malformations.[86] Opioid use similarly associates with cardiac and neural tube defects, though polysubstance confounding complicates isolation of effects.[87] These risks stem from direct placental transfer and neurotoxic impacts, supported by animal models and human registries.[88] Maternal pre-pregnancy obesity (BMI ≥30 kg/m²) independently elevates congenital anomaly risks in a severity-dependent manner, with meta-analyses estimating 20-50% higher odds for neural tube defects, cardiac anomalies, and anorectal malformations.[89] This association holds after adjusting for diabetes and smoking, potentially via inflammatory cytokines or altered folliculogenesis affecting gamete quality preconceptionally.[90] Overweight (BMI 25-29.9) shows intermediate risks, underscoring lifestyle-mediated body composition as a modifiable factor.[91] Evidence for other behaviors like caffeine intake (>200 mg/day) or psychological stress remains inconsistent for structural defects; large case-control studies find no robust links to malformations after confounder adjustment, though stress may exacerbate folic acid-sensitive anomalies in unsupplemented women.[92][93] Prioritizing cessation of smoking, alcohol, and drugs, alongside weight management, targets empirically supported pathways in etiology.Paternal Contributions
Advanced paternal age, defined as fathers over 35–40 years, elevates the risk of de novo germline mutations in sperm due to accumulated replication errors during spermatogenesis, contributing to offspring congenital anomalies such as achondroplasia, craniosynostosis syndromes, and chromosomal disorders.[94] A systematic review of cohort studies found that fathers aged 40 and older had a 1.5–2-fold increased odds of cardiovascular, urogenital, and facial defects compared to those under 25, with risks persisting after adjusting for maternal factors.[75] Population-based data from over 5 million births indicate advanced paternal age specifically heightens chromosomal anomaly rates, including trisomies, independent of maternal age.[95] Paternal smoking preconception or periconceptionally damages sperm DNA via oxidative stress and mutagens, associating with a 1.2–1.6-fold elevated risk of congenital heart defects, orofacial clefts, and musculoskeletal anomalies in offspring.[96] Meta-analyses of case-control studies confirm this link, showing dose-dependent effects where heavy smokers (>10 cigarettes/day) impart higher risks than light smokers, with mechanisms involving heritable epigenetic alterations in sperm.[97] These associations hold after controlling for maternal smoking and socioeconomic confounders, though some observational biases may inflate estimates due to residual unmeasured variables.[98] Occupational exposures to solvents, pesticides, lead, and heavy metals in fathers preconceptionally correlate with specific malformations, such as neural tube defects and limb reductions, through sperm-mediated genotoxicity.[99] For instance, paternal lead exposure doubles the odds of congenital malformations in cohort studies of industrial workers, attributable to impaired spermatogenesis and DNA strand breaks.[100] Laboratory and agricultural occupations show 1.3–2.0 odds ratios for musculoskeletal defects, linked to volatile organic compounds disrupting paternal meiosis.[101] Evidence from registries underscores these risks, though causation requires further prospective validation amid potential recall biases in self-reported exposures.[102] Sperm DNA fragmentation index (DFI >30%) from fragmentation or apoptosis precursors predicts embryonic genomic instability, raising birth defect risks via aneuploidy and failed DNA repair in zygotes.[103] Clinical data from IVF cohorts demonstrate DFI elevation associates with 1.5–3-fold higher rates of major anomalies, including cardiac and genitourinary, as fragmented paternal DNA evades oocyte repair mechanisms.[104] Paternal metabolic comorbidities like obesity or diabetes exacerbate DFI, indirectly amplifying defect odds through impaired sperm protamination.[105] These findings, derived from semen analyses and birth outcome linkages, highlight sperm quality as a modifiable paternal determinant, though thresholds for clinical intervention remain debated.[106]Socioeconomic Influences
Lower socioeconomic status (SES) has been associated with increased risks of certain birth defects, particularly through indirect pathways such as inadequate prenatal care, poor nutrition, and higher exposure to environmental risk factors. A meta-analysis of observational studies found that lower maternal SES is modestly linked to a higher incidence of congenital heart defects (CHDs), with an odds ratio of approximately 1.2 across pooled data from multiple cohorts.[107] This association persists after adjusting for confounders like maternal age, though evidence for causality remains indirect, mediated by factors including smoking prevalence and limited access to folic acid supplementation, which prevents neural tube defects.[108] Household-level SES indicators, such as neighborhood deprivation, correlate more strongly with risks than individual measures in some populations. For instance, a California birth cohort study reported elevated odds ratios (1.5–2.0) for neural tube defects and selected cardiac anomalies in lower SES households, attributed to clustered risks like substandard housing and reduced healthcare utilization.[108] Similarly, lower neighborhood SES during early pregnancy has been tied to increased CHD prevalence, with area-based metrics like income quintiles showing dose-response gradients.[109] However, Mendelian randomization analyses indicate limited direct genetic confounding, suggesting environmental and behavioral mediators predominate.[110] Globally, congenital anomaly mortality rates are markedly higher in low- and middle-income countries, where SES disparities exacerbate underreporting and limited intervention access; WHO data from 2012 documented rates exceeding 100 deaths per million in parts of sub-Saharan Africa and South Asia, versus under 10 in high-income regions. These patterns align with SES gradients, though diagnostic ascertainment biases may inflate apparent risks in underserved areas due to survival outcomes rather than incidence alone. For chromosomal anomalies like Down syndrome, low maternal SES specifically elevates nondisjunction risks via meiosis II errors, potentially from nutritional deficiencies or oxidative stress.[111] Higher parental education, a proxy for SES, consistently shows protective effects across studies, with each additional year reducing anomaly risks by 5–10% through informed health behaviors.[110] Despite these findings, overall evidence for SES-birth defect links is heterogeneous, with some registries showing null associations after stratification by defect type, underscoring the need for causal pathway dissection beyond correlative data.[108]Prevention Strategies
Nutritional Interventions
Folic acid supplementation periconceptionally has been shown to substantially reduce the risk of neural tube defects (NTDs), including spina bifida and anencephaly, which affect approximately 1 in 1,000 pregnancies worldwide without intervention.[112] A landmark randomized controlled trial conducted by the Medical Research Council in 1991 demonstrated that 4 mg daily of folic acid reduced NTD recurrence by 72% in women with prior affected pregnancies. Meta-analyses of observational and interventional studies confirm a protective effect, with odds ratios ranging from 0.67 for multivitamin use containing folic acid to broader reductions in congenital anomalies by up to 20-30% with supplementation.[113] [114] Health authorities recommend 400 μg daily for women of childbearing age starting one month before conception through the first trimester, as NTDs occur early in embryogenesis before many pregnancies are confirmed.[115] Food fortification with folic acid, implemented in over 80 countries since the late 1990s, has further decreased NTD prevalence by 20-50% in fortified populations, such as a 35% reduction in the United States post-1998 mandatory enrichment of grains.[116] This population-level intervention leverages staple foods to address suboptimal dietary intake, where natural folate sources like leafy greens provide insufficient bioavailable forms compared to synthetic folic acid.[117] However, supplementation alone does not eliminate all cases, as 20-30% of NTDs may involve non-folate-sensitive mechanisms, underscoring the need for combined strategies.[118] Iodine supplementation prevents iodine deficiency disorders, including congenital hypothyroidism and endemic cretinism, characterized by severe intellectual disability, growth stunting, and neurological deficits.[119] In deficient regions, maternal iodine inadequacy during pregnancy impairs fetal thyroid hormone production critical for brain development, with supplementation trials showing up to 16-point IQ gains in offspring and near-eradication of cretinism where universal salt iodization was adopted.[120] The World Health Organization endorses 250 μg daily for pregnant women in endemic areas, reducing miscarriage, stillbirth, and congenital anomalies linked to deficiency.[121] Evidence from controlled studies in severe deficiency zones confirms prevention without excess risk in non-deficient populations when intake remains moderate.[122] Limited evidence supports other nutrients for specific defects; for instance, adequate maternal vitamin A intake may mitigate certain cardiac anomalies, but excess poses teratogenic risks, necessitating caution beyond recommended levels.[123] Overall, targeted nutritional interventions grounded in deficiency correction yield the most verifiable reductions in preventable birth defects, with efficacy tied to timing and dosage adherence.[124]Behavioral Modifications
Behavioral modifications during preconception and pregnancy significantly reduce the incidence of certain birth defects by minimizing exposure to known teratogens. Empirical evidence from cohort studies indicates that avoiding modifiable risk factors such as tobacco, alcohol, and illicit substances can lower rates of congenital malformations, including neural tube defects, orofacial clefts, and cardiac anomalies.[125] [126] For instance, preconception counseling promoting these changes has been associated with improved adherence to risk-reducing behaviors in randomized trials.[127] Abstinence from alcohol consumption prevents fetal alcohol spectrum disorders (FASDs), a leading preventable cause of intellectual disability and craniofacial malformations. The Centers for Disease Control and Prevention (CDC) recommends complete avoidance of alcohol if pregnancy is possible, as no safe threshold exists; global prevalence of prenatal alcohol exposure is estimated at 9.8%, correlating with FAS prevalence of up to 2-5% in affected populations.[128] [129] Screening and brief interventions during routine prenatal visits have demonstrated effectiveness in reducing continued use, with systematic reviews showing decreased incidence of alcohol-related birth defects when implemented universally.[130] Smoking cessation, particularly before or early in the first trimester, mitigates risks of preterm birth and specific defects like cleft lip and palate, which are elevated 1.5-2-fold among exposed fetuses. A 2019 analysis of over 10 million U.S. births found that quitting smoking reduced preterm delivery risk by up to 20%, even among heavy smokers, independent of other factors.[131] [132] Periconceptional tobacco avoidance also lowers congenital heart defect odds by addressing nicotine's interference with fetal organogenesis, as evidenced by prospective studies linking passive exposure to similar, though attenuated, harms.[133] [134] Avoiding illicit drugs and non-prescribed medications prevents disruptions to embryonic development, with methamphetamine and cocaine linked to cardiac and limb defects in exposed cohorts. Behavioral strategies include occupational adjustments to evade environmental teratogens like solvents or pesticides, which public health campaigns have shown to decrease malformation rates through awareness and relocation.[126] [125] Preconception optimization of chronic conditions via lifestyle adherence, such as glycemic control in diabetes, further averts anomalies like caudal regression syndrome, supported by longitudinal data emphasizing early intervention.[135] Overall, these modifications, when integrated into family planning, yield measurable reductions in attributable birth defect fractions.[136]Medical and Technological Preventions
Medical preventions for certain birth defects include vaccinations against maternal infections known to cause congenital anomalies. The measles-mumps-rubella (MMR) vaccine, administered prior to pregnancy, prevents rubella infection, which can lead to congenital rubella syndrome characterized by cardiac, ocular, and auditory defects in up to 90% of cases when infection occurs in the first trimester.[137] Similarly, the varicella vaccine protects against chickenpox, reducing the risk of fetal varicella syndrome, which involves limb hypoplasia, skin scarring, and neurological damage, with incidence rates approaching 2% in maternal infections during weeks 8-20 of gestation.[138] These live vaccines are contraindicated during pregnancy due to theoretical risks but achieve 97% efficacy against rubella with one dose.[139] Immunoprophylaxis with Rho(D) immune globulin (RhoGAM) prevents hemolytic disease of the fetus and newborn (HDFN) in Rh-negative mothers carrying Rh-positive fetuses. Administered intramuscularly at 28 weeks gestation and within 72 hours postpartum if the infant is Rh-positive, RhoGAM suppresses maternal anti-D antibody production, reducing sensitization rates from historical levels of 13-16% to less than 0.3%.[140] This intervention has averted severe anemia, hydrops fetalis, and kernicterus in subsequent pregnancies since its introduction in the 1960s.[141] Technological advancements in assisted reproductive technologies enable preimplantation genetic testing (PGT) to avoid implantation of embryos carrying genetic defects. During in vitro fertilization (IVF), biopsied embryonic cells are analyzed for monogenic disorders (PGT-M), structural rearrangements (PGT-SR), or aneuploidy (PGT-A), allowing selection of unaffected embryos and preventing births of conditions like cystic fibrosis or Down syndrome in at-risk couples.[142] PGT-M efficacy exceeds 95% for single-gene mutations when combined with linkage analysis, though it requires IVF and does not address de novo or multifactorial defects.[143] Carrier screening technologies, including expanded panels for over 100 recessive disorders via next-generation sequencing, inform PGT use and have reduced affected births in screened populations by up to 50% in some cohorts.[144] Prenatal diagnostic technologies, such as noninvasive prenatal testing (NIPT) using cell-free fetal DNA from maternal blood, detect chromosomal anomalies like trisomy 21 with over 99% sensitivity from 10 weeks gestation, enabling informed reproductive decisions that prevent affected births through selective termination.[145] Invasive procedures like chorionic villus sampling (CVS) or amniocentesis provide definitive diagnosis for targeted anomalies, with CVS yielding results by 10-13 weeks.[145] These methods, while diagnostic, contribute to prevention by facilitating early intervention or pregnancy management in high-risk cases, though they carry miscarriage risks of 0.1-0.5% for CVS.[145]Diagnosis and Screening
Prenatal Diagnostic Methods
Prenatal diagnostic methods for birth defects distinguish between non-invasive screening tests, which estimate risk probabilities, and invasive diagnostic procedures, which provide definitive genetic or cytogenetic confirmation. Approximately 3% to 5% of pregnancies involve detectable birth defects or genetic disorders, with chromosomal abnormalities occurring in about 1 in 150 live births; early detection enables informed decision-making and potential interventions.[146] Fetal ultrasound serves as the primary imaging modality for structural anomalies, with routine second-trimester anatomy scans (18-20 weeks) detecting major malformations at rates of 50-80% overall, varying by type—such as 95-99% for abdominal wall defects when combining first- and second-trimester assessments, but lower (around 30-50%) for certain cardiac anomalies. First-trimester scans (11-14 weeks) identify increased nuchal translucency associated with aneuploidies or cardiac issues, offering 85-90% sensitivity for Down syndrome when integrated with blood markers. Detection improves with operator expertise and equipment quality, though limitations include obesity-related acoustic shadowing and subtle anomalies missed until later gestation.[147][148][149] Non-invasive prenatal testing (NIPT), utilizing cell-free fetal DNA from maternal blood starting at 10 weeks, screens for common aneuploidies with high accuracy: over 99% sensitivity and specificity for trisomy 21, 85-98% for trisomy 18, and 87% for trisomy 13, though false positives occur due to maternal factors or confined placental mosaicism. NIPT detects some microdeletions and sex chromosome anomalies but does not assess structural defects or all monogenic disorders, with positive predictive values ranging 83-93% depending on maternal age and prevalence. It reduces the need for invasive tests by confirming low-risk results in 98% of cases, but abnormal findings require diagnostic verification.[150][151][152] Invasive diagnostics include chorionic villus sampling (CVS) at 10-13 weeks, which analyzes placental cells for karyotype, microarray, or sequencing to confirm chromosomal, genetic, or molecular defects with near-100% accuracy for sampled tissues. Procedure-related miscarriage risk is approximately 0.5%, comparable to background rates in low-risk pregnancies, with additional rare complications like infection or limb reduction if performed before 10 weeks. Amniocentesis, from 15-20 weeks, examines fetal cells from amniotic fluid similarly, yielding definitive results for aneuploidies and select structural correlates, with miscarriage risk of 0.1-0.3% above baseline. Both procedures carry infection or preterm labor risks but enable comprehensive testing, including for conditions indicated by prior screening.[153][154][155] Advanced techniques like fetal magnetic resonance imaging (MRI) complement ultrasound for detailed soft-tissue evaluation of central nervous system or thoracic anomalies undetected sonographically, though it is not routine due to cost and availability. Microarray analysis in invasive samples identifies submicroscopic copy number variants missed by standard karyotyping, enhancing detection of developmental disorders. Overall prenatal detection rates for major anomalies reach 69% in structured programs, with ongoing refinements in protocols improving outcomes without elevating procedural risks unduly.[156][157]Postnatal Evaluation
Postnatal evaluation of birth defects commences immediately after delivery with a comprehensive physical examination conducted by pediatricians or neonatologists to identify external structural anomalies, dysmorphic facial features, and syndromic patterns suggestive of underlying genetic or developmental issues.[158] This examination includes assessment of vital signs, anthropometric measurements, and systematic inspection of all body systems, such as palpation for organomegaly, evaluation of limb symmetry, and neurological checks for tone and reflexes, enabling early detection of conditions like cleft lip/palate or limb reductions that may not have been apparent prenatally.[158] In cases where prenatal anomalies were identified, postnatal confirmation is prioritized, often revealing discrepancies; for instance, up to 20-30% of prenatally diagnosed structural anomalies may show phenotypic differences or additional findings upon neonatal reassessment.[159] Routine newborn screening forms a cornerstone of postnatal evaluation, typically performed within 24-48 hours of birth via heel-prick blood sampling to test for metabolic, endocrine, and hemoglobin disorders such as phenylketonuria, congenital hypothyroidism, and sickle cell disease, with programs screening for 30-60 conditions depending on jurisdiction.[160] [161] Additional universal screens include otoacoustic emissions or auditory brainstem response for hearing loss, detecting up to 1-3 per 1,000 affected infants, and pulse oximetry for critical congenital heart defects, which identifies about 0.02-0.1% of cases with sensitivity exceeding 75% when performed after 24 hours of age.[160] [162] These non-invasive tests, mandated by law in most U.S. states and internationally recommended by bodies like the WHO, facilitate early intervention but miss structural defects like neural tube anomalies unless clinically evident.[161] For suspected anomalies, targeted diagnostic imaging and laboratory tests follow, including radiographs for skeletal dysplasias, cranial ultrasounds for brain malformations, and echocardiograms to confirm cardiac defects, with the latter essential as prenatal echocardiography may overestimate or underestimate severity in 10-20% of cases.[163] Multidisciplinary teams, involving geneticists, surgeons, and subspecialists, coordinate further evaluations such as renal ultrasounds for genitourinary issues or MRI for central nervous system anomalies, ensuring holistic assessment; studies indicate that 15-25% of neonates with prenatally undetected anomalies are diagnosed postnatally through such protocols.[164] Early referral to specialized centers improves outcomes, as delays in confirming diagnoses like congenital diaphragmatic hernia can elevate morbidity.[165] Limitations persist, however, with up to 50% of genetic etiologies in complex anomalies requiring advanced testing beyond initial evaluation, underscoring the need for ongoing surveillance in the first weeks of life.[166]Genetic Testing Advances
Non-invasive prenatal testing (NIPT), utilizing cell-free fetal DNA from maternal blood, represents a major advance in screening for chromosomal anomalies linked to birth defects, achieving detection rates over 99% for trisomy 21, 18, and 13 since its clinical introduction in 2011.[167] Expanded NIPT protocols, developed post-2020, now incorporate analysis for sex chromosome abnormalities, microdeletions, and select copy number variants, broadening applicability to sub-chromosomal defects that contribute to congenital malformations.[168] These improvements stem from enhanced sequencing depth and bioinformatics algorithms, reducing false positives to under 0.1% for common trisomies in high-risk populations, though confirmatory invasive testing remains essential for positive results due to residual risks of confined placental mosaicism.[169] Whole exome sequencing (WES) has transformed prenatal diagnosis for fetuses exhibiting ultrasound-detected structural anomalies, such as cardiac or skeletal defects, where standard karyotyping or microarray yields negative results in up to 70% of cases. Applied to amniotic fluid or chorionic villus samples, WES targets the protein-coding genome to identify monogenic variants, with diagnostic rates of 20-40% reported in cohorts of anomalous fetuses from 2020 onward.[170] A 2022 multicenter study integrated WES into routine prenatal workflows, yielding actionable diagnoses in 29% of previously undiagnosed cases, enabling informed family planning and targeted postnatal management.[171] For specific anomalies like skeletal dysplasias, WES has identified causative mutations in genes such as COL1A1 or FGFR3, with a 2024 analysis showing improved resolution over targeted panels.[172] Rapid whole genome sequencing (WGS) extends these capabilities, offering comprehensive variant detection including non-coding regions, with turnaround times reduced to days via ultra-rapid protocols implemented in specialized centers since 2021. In prenatal settings, WGS has diagnosed complex syndromes underlying multiple congenital anomalies, with yields up to 40% in trio analyses incorporating parental genomes for de novo variant filtering.[173] Expanded carrier screening via next-generation sequencing panels, updated through 2025, now covers over 100 recessive conditions predisposing to birth defects, facilitating preconception risk assessment with carrier detection rates exceeding 90% for prevalent disorders like cystic fibrosis.[174] These technologies collectively shift diagnosis from phenotypic observation to molecular etiology, though challenges persist in variant interpretation, with only 85% of disease-associated variants in exonic regions, underscoring the need for ongoing validation against functional assays.[175]Management and Treatment
Surgical and Therapeutic Interventions
Surgical interventions form the cornerstone of treatment for many structural birth defects, particularly those affecting the heart, craniofacial structures, and neural tube, with procedures tailored to the specific anomaly and timed to optimize outcomes based on infant stability and growth. For congenital heart defects, which comprise about one-quarter of severe birth defects, surgeries such as closure of atrial or ventricular septal defects, patent ductus arteriosus ligation, and valve repairs are performed, often in the neonatal period or infancy to prevent complications like heart failure.[176] In the United States, critical congenital heart defects necessitate surgical or catheter-based intervention within the first year of life for approximately 25% of cases.[177] Craniofacial anomalies like cleft lip and palate undergo reconstructive surgery, with lip repair typically at 3-6 months of age following the "rule of 10s" (age >10 weeks, weight >10 pounds, hemoglobin >10 g/dL) to minimize risks, and palate repair at 6-12 months to facilitate feeding and speech development.[178] For neural tube defects such as spina bifida, postnatal surgical closure of the defect occurs shortly after birth to prevent infection, while fetal surgery, as demonstrated in the 2011 Management of Myelomeningocele Study (MOMS), performed between 19-25 weeks gestation, reduces the need for cerebrospinal fluid shunts by 41% and increases independent walking rates.[179] Therapeutic interventions complement surgery through multidisciplinary approaches including physical, occupational, and speech therapies to address functional deficits, such as motor delays in spina bifida or speech impediments post-cleft repair.[180] Assistive devices like orthopedic braces for limb anomalies or cochlear implants for associated hearing loss support long-term function, while medications manage symptoms in functional birth defects, though evidence for broad efficacy remains limited outside specific contexts like arrhythmia in heart defects.[180] Catheter-based interventions, such as device closure for septal defects, offer non-surgical alternatives for select cardiac anomalies, reducing recovery time compared to open procedures.[176]Long-Term Care and Outcomes
Long-term care for individuals born with birth defects requires coordinated, multidisciplinary management to mitigate complications, support development, and enhance quality of life, often extending from infancy through adulthood. This approach typically involves teams of specialists including pediatricians, genetic counselors, physical and occupational therapists, surgeons, and mental health professionals, who address organ-specific issues, neurodevelopmental delays, and secondary conditions such as orthopedic deformities or cognitive impairments. Early intervention, including therapies and educational support, has been shown to improve functional outcomes, though access to such care varies by defect severity and socioeconomic factors.[181][182][183] Survival outcomes have advanced due to improvements in neonatal care and surgical techniques, with overall 1-year survival for major defects reaching 95% and 10-year survival exceeding 93% in population-based registries. For isolated anomalies, 10-year survival stands at 96.9%, though risks remain highest in the first year, particularly for cardiovascular and neural tube defects. Congenital heart defects illustrate variability, with 80% of those born between 1980 and 1997 surviving to age 35, but ongoing morbidity affects neurocognition, growth, and mental health in up to 50% of cases. Globally, birth defects account for substantial disability-adjusted life years, underscoring persistent long-term burdens despite reduced neonatal mortality.[184][185][186] Despite high survival, many survivors require lifelong monitoring for sequelae such as renal dysfunction, infertility, or secondary cancers, with multidisciplinary follow-up essential for conditions like spina bifida or achondroplasia to prevent complications like hydrocephalus or spinal stenosis. Quality-of-life metrics reveal elevated rates of chronic illness and dependency; for instance, children with rare structural anomalies of the digestive system achieve over 84% 10-year survival but face recurrent hospitalizations. Factors influencing outcomes include defect complexity, associated syndromes, and prenatal diagnosis, which enables proactive management but does not eliminate risks of preterm birth or low birth weight exacerbating morbidity. In resource-limited settings, inadequate follow-up amplifies disparities, leading to higher disability rates.[187][188][189]This map illustrates the global distribution of disability-adjusted life years attributable to congenital anomalies, highlighting regions with higher long-term burdens from inadequate care infrastructure.[4]
Emerging Therapies
In 2025, personalized CRISPR-based gene editing emerged as a pioneering therapy for ultrarare genetic birth defects, with the first successful treatment administered to an infant with a novel mutation causing severe metabolic dysfunction. The procedure, developed through a rapid workflow involving base editing to correct a specific liver gene variant, was delivered via intravenous infusion six months after diagnosis, resulting in the child's improved growth and thriving without reported adverse effects.[190][191] This N-of-1 approach, customized for unique variants untreatable by standard methods, demonstrated feasibility for monogenic congenital disorders, though long-term efficacy requires further monitoring in expanded cohorts.[192] In utero gene therapy represents another frontier, with the inaugural human fetal application reported in February 2025 at the University of California, San Francisco, targeting inherited metabolic diseases via vector delivery to amniotic fluid. Preclinical models have shown this prenatal strategy can achieve higher transduction efficiency in target organs compared to postnatal administration, potentially mitigating irreversible damage from defects like ornithine transcarbamylase deficiency.[193] Clinical translation remains challenged by risks of immune response and off-target edits, necessitating refined adeno-associated virus (AAV) vectors tailored for fetal tolerance.[194] Stem cell therapies, particularly mesenchymal stem cells derived from placental tissue, have advanced for structural birth defects such as spina bifida through fetal surgery integration. In ongoing trials at UC Davis, since 2022, allogeneic stem cells injected during maternal hysterotomy have promoted neural tissue repair in utero, with preliminary data from treated infants showing improved lower limb function and reduced hydrocephalus incidence compared to historical controls.[195] A 2024 extension of this CuRe trial, funded with $15 million, aims to enroll additional participants to assess durability of ambulation gains into childhood.[196] Minimally invasive fetal surgery techniques have evolved for congenital anomalies like myelomeningocele and congenital diaphragmatic hernia, incorporating fetoscopy to reduce maternal morbidity. By 2025, endoscopic approaches enabled valve ablation for lower urinary tract obstruction, preserving renal function in 70-80% of cases versus 50% with postnatal shunting alone, per multicenter registries.[197] These interventions, refined with high-resolution imaging and bioengineered patches, expand treatability to earlier gestations, though randomized evidence is limited to select centers due to ethical constraints on sham surgeries.[198] Ongoing refinements prioritize hybrid open-fetoscopic methods to balance efficacy with preterm labor risks.[199]Epidemiology
Global Burden and Trends
Congenital anomalies, also known as birth defects, impose a significant global health burden, affecting an estimated 2-3% of live births worldwide, with higher rates of 4-6% reported in some population-based studies including chromosomal and genetic conditions.[200] In 2021, the Global Burden of Disease study estimated 7.2 million prevalent cases of congenital birth defects globally, accompanied by 530,000 associated deaths, predominantly among children under 5 years.[201] These conditions contribute substantially to neonatal and infant mortality, accounting for approximately 240,000 deaths within the first 28 days of life annually, representing about 11% of all neonatal deaths.[4] Disability-adjusted life years (DALYs) lost to congenital anomalies remain high, with musculoskeletal and limb anomalies driving the majority of incidence and prevalence burdens.[202] Over the past three decades, trends indicate a decline in age-standardized rates of mortality and DALYs attributable to congenital birth defects, reflecting improvements in prenatal screening, folic acid supplementation, and access to surgical interventions in higher-income regions.[203] Global deaths from these conditions decreased from 902,741 in 1990 to 475,816 in 2021, a reduction driven by public health measures despite population growth leading to a 6.68% rise in affected children aged 0-14 years to 31.64 million.[203] However, absolute prevalence has shown mixed patterns, with some subtypes like congenital heart defects exhibiting stable or increasing incidence in low-resource settings due to under-detection in earlier periods and persistent environmental risk factors.[204] Overall, the worldwide burden, measured by DALYs, has decreased by around 35% for certain categories like digestive anomalies from 1990 to 2021, though low socio-demographic index regions continue to bear disproportionately higher rates, with 94% of serious birth defects and 95% of related deaths occurring in low- and middle-income countries.[205][206]Regional and National Data
Prevalence and burden of congenital birth defects exhibit significant regional variations, largely correlating with sociodemographic index (SDI) levels. In 2021, the Global Burden of Disease study reported a prevalence of 1,693 per 100,000 children aged 0-14 in low-SDI regions, compared to 1,521 per 100,000 in high-SDI regions; however, low-SDI areas bore disproportionately higher mortality (199,408 deaths) and disability-adjusted life years (DALYs).[203] East Asia showed the lowest regional prevalence at 1,221 per 100,000, alongside the largest mortality reduction (EAPC -5.29% from 1990-2021), while Oceania experienced prevalence increases (EAPC 0.27).[203] Low- and middle-income countries account for 94% of severe congenital disorders worldwide, driven by factors such as inadequate nutrition, infections, and limited prenatal care.[4] National data reveal further disparities. In the United States, approximately 1 in 33 infants (about 3%) is born with a birth defect, based on CDC surveillance encompassing major structural and functional anomalies.[28] India reports the highest absolute caseload, with 8.29 million affected children aged 0-14 in 2021, reflecting its large population despite moderate per capita rates.[203] Brunei Darussalam had the highest national prevalence at 2,444.81 per 100,000, while the Cook Islands recorded the lowest at 1,071.20 per 100,000.[203] In sub-Saharan Africa, country-specific studies indicate elevated rates, such as 9.62% in Kenya and 7.4% in Egypt, exceeding global averages and underscoring underreporting and access challenges in the region.[13]| Selected National Prevalence Rates (per 100,000 children 0-14, 2021) | Rate |
|---|---|
| Brunei Darussalam | 2,444.81 |
| Cook Islands | 1,071.20 |
| United States (birth incidence approx. 3,000 per 100,000) | ~3,000 |
